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Abstract 
The purpose if thus study is to explore the impacts of high authority regulation and enforcement to 
supply chain management practices. As one of the most regulated industries, the pharmaceutical 
industry was chosen as the research context. More specifically, this study concentrates on the pro-
cess of managing supplier’s compliance to guidelines imposed by the European Commission, 
commonly called as the Good Manufacturing Practice (GMP). The research context provides a 
prominent ground for researching the main effects of rigorous authority supervision that may have 
significant impacts to both business and society. 
Theoretical part of this study concentrates on the relevant literature on supply chain manage-
ment, supplier management, supply chain risk management and supply chain sustainability man-
agement. This literature review serves as a theoretical framework to understand what are preva-
lent, or normal, processes and assumptions in these different practices. This understanding is im-
portant for identifying the anomalies brought by high authority regulation and enforcement. 
The research was conducted by interviewing informants from six different pharmaceutical com-
panies on their personal perceptions and company’s processes. All the informants had a major role 
in their company’s supplier GMP-compliance process, thus having significant internal knowledge. 
A general framework on the supplier GMP-compliance management process is proposed based on 
the findings. 
I conclude that rigorous authority regulation and enforcement has several major impacts on how 
companies manage their suppliers, including disintegration of sub-processes, creation of depart-
mental silos and shifting focus towards compliance itself rather than efficiency or rationality of the 
process. Furthermore, regulations limit risk management options that companies can exercise, 
which can lead to severe supply chain disruptions. Finally, through authority enforcement and 
certification programs, there is an unintentional shift of responsibility from industry towards the 
authorities. 
Contributions of this study reach beyond expanding theory – the balance between industrial in-
ternal self-control and need of regulatory interference and supervision is in headlines now perhaps 
more than ever before, not least because of the rise of sustainability initiatives. While adding regu-
lation may at first seem as straight-forward approach, it has implications that are critical to recog-
nize before imposing new requirements.  
Keywords  supply chain management, supplier management, compliance, authority enforcement, 
risk management, sustainable supply chain management, Good Manufacturing Practice, pharma-
ceutical industry 
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1. INTRODUCTION 
1.1 The pharmaceutical industry, GMP-compliance and impacts of regulation 
Surprisingly little research has been done in relation to the pharmaceutical industry practices 
in general, given its formidable size and undisputed importance. The industry has many 
specific features, which may hinder the generalization of research results to other industry 
fields and vice versa, but also make the research essential: pharmaceuticals are saving lives, 
but as can be seen from the history, they have also taken lives when something has gone 
wrong. It is not unfair to say that pharmaceutical industry has an impact on every one of us, 
which is also a reason for its intense and strict regulations.  
  
Pharmaceutical industry is perhaps the most regulated industry and, besides regulations, it is 
also known for intense authority enforcement of those regulations. All critical activities 
related to delivering the pharmaceuticals to patients are subject to a specific license. In the 
context of this industry, authorities have a strong mandate in controlling compliance to the 
regulations, and enforcement acts such as import restrictions or withdrawing licenses are seen 
regularly. This is in addition to the tight industry self-control.  
  
In the research context of pharmaceutical industry, this study focuses on the significance and 
nature of GMP-compliance risk, a term that is specific to the pharmaceutical industry. GMP 
refers to the good manufacturing practices, or the prevalent regulations starting from raw 
material manufacturing and reaching to analyzing and releasing a finished pharmaceutical 
batch for sale. Compliance in this context refers to adhering and conforming to pre-defined 
guidelines and regulations that have been set by an external party (or parties) to ensure safety 
and benefits of the society rather than individual corporations or industries. This definition 
includes a notion that industry’s self-control has not seen sufficient and reliable, which is 
quite self-evident from history of the pharmaceutical industry discussed in later chapters. The 
scope of this study has been further limited to external supply chain GMP-compliance risk, 
or in other words, the risk arising from outsourcing manufacturing and related activities and 
not being able to sufficiently control GMP-compliance level of suppliers. In the context of 
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the pharmaceutical industry, the purpose of this thesis is to study how significant the GMP-
compliance risk is seen by the industry today, what are the current supply chain GMP-
compliance risk management practices, and how have the regulations and strong authority 
enforcement shaped them compared to conventional supply chain and risk management. 
  
Motivation for the study and the scope merged from a perceived growth in importance of the 
topic: different authorities seemed to increase their monitoring and more actively impose 
sanctions for non-compliances. At the same time, GMP-regulations are being updated to 
widen their scope and impose stricter requirements: for example, besides adding new 
requirements, EU GMP chapter 7 was updated in 2012 to concern all outsourced activities, 
instead of the earlier scope of contract manufacture and analysis. Finally, as with other 
industries, pharmaceutical supply chains have become much more complex, shifting a lot of 
activities to developing countries. As the manufacturing is taking place much further, 
managing one’s supply chain becomes more complex and calls for new means.   
  
All this has led to increasing number of pharma supply chain disruptions related to GMP 
violations, which can have drastic consequences. From the business side, consequences can 
vary from withdrawing certain batches from the markets to cancelling entire product lines, 
as well as company image and reputational issues. From societal perspective, these 
disruptions can cause world-wide supply shortages of critical medicines.  
 
Regulations naturally also exist outside the pharmaceutical industry, even if they would not 
be overseen and enforced as rigorously as with the pharmaceuticals. Many other industries, 
such as banking and insurance, are currently experiencing a move to a significantly stricter 
regulatory environment. Furthermore, ever-stricter regulations related to sustainability are 
affecting virtually all businesses, regardless of their line of business. It is quite obvious that 
increasing regulations will have an impact on companies operate, some of them as intended 
by regulators, but also some unintended impacts as byproducts of the requirements will 
certainly appear.  
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These byproducts might have significant negative effects for business as well as for the 
society and it is thus important to identify and understand them, for businesses to avoid 
unintentional processes that might cause inefficiencies and harm the company and for 
authorities to understand these byproducts when developing existing and new regulations. In 
a more general context within theoretical fields of supply chain management, supply chain 
risk management and supply chain sustainability management, this study will explore the 
byproducts that strong regulation produces in supplier management practices. To identify 
these regulation-caused byproducts, supplier management practices in the pharmaceutical 
industry are compared to traditional approaches identified from the literature.  
 
The research problems discussed above are reflected in the following questions that together 
constitute the research question for this thesis: 
What is the significance and nature of Good Manufacturing Practice compliance risk? 
How is supplier and risk management constructed in a highly regulated and enforced 
environment? 
What are the impacts that strong regulation and authority enforcement impose to supplier 
and risk management practices? 
 
1.2 Outline for the thesis 
This thesis situates itself among three main theoretical fields: supply chain management, risk 
management and sustainability management. From the perspective of this thesis, sub-themes 
of these main theoretical fields concentrating on supply chain management and supplier 
management concepts are the most relevant ones. These theoretical fields, even though being 
their own research areas, are intertwined and borrowing from each other.  
 
The reason for focusing on supply chain management and risk management is quite clear: 
these are the main theoretical fields explaining the background and the very basic 
assumptions related to this thesis. Without reviewing these two fields, it would be very hard 
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to define the upper-level context relevant to this thesis or reflect the study results to areas 
outside the pharmaceutical industry. Compared to these two research areas, importance of 
sustainability management to this thesis is not as obvious and requires further elaboration. 
 
As mentioned above, the pharmaceutical industry, and GMP-compliance being one of its 
specific characteristics, have remained understudied till to date. Furthermore, management 
of compliance in general has attracted little interest. Sustainability management is one of the 
rare theoretical fields that studies compliance management in a supply chain context and is 
thus of special interest for this thesis: it deals with managing compliance to certain standards, 
and even though there are some differences to the GMP-environment, management of 
sustainability on supply chains is a fairly good match with supply chain GMP-compliance 
management.  
 
Sustainability management is still a new area, but it has withdrawn a lot of attention in recent 
years. Its theoretical context is built around contemporary and complex supply chains, 
extending around the whole world, that is also characteristic of pharmaceutical supply 
chains. For this thesis, sustainability management is a mean to extend the theoretical surface 
to include compliance-specific features from a general, not an industry-specific, perspective. 
It should be beard in mind, however, that sustainability is not a perfect analogue to GMP: 
one major difference between the two topics is that where authorities are the main party 
monitoring and imposing GMP-compliance, NGOs and other non-authority stakeholders are 
more important in sustainability enforcement.  
 
The higher-level purpose for this thesis can be described as follows: instead of being an 
empirical testing field for the prevalent theories, the pharmaceutical industry and GMP-
compliance provides an interesting setting for researching the effects of high authority 
regulation and enforcement in relation to these prevalent theories. This thesis will thus 
research how the assumptions and generally accepted practices are shaped by the specific 
setting examined. 
5 
 
The outline for the thesis is as follows: first chapters will introduce the relevant literature 
field, starting from the outlying area of supply chain management in general and specifically 
supplier management and supply chain risk management practices. The final part of the 
literature review will concentrate on relevant literature on sustainability from supply chain 
management perspective. After the literature review, methodology chapter will introduce 
research questions, research context and how the research was conducted. Before going to 
the actual results, chapter 5 will act as an introduction to the empirical context of the research, 
the pharmaceutical industry, and its specific characteristics. This will be followed by 
presentation of the research results and main conclusions and discussion. I will conclude this 
thesis with managerial implications and further research suggestions. 
  
2. THEORETICAL APPROACHES TO SUPPLY CHAIN MANAGEMENT 
One of the earliest academics emphasizing the importance of purchasing and suppliers was 
Porter (1975), who identified them as two of the five critical forces that affect industry 
competitive nature. The strategic importance of purchasing and supplier decisions has 
subsequently been emphasized by many authors and today is a generally accepted notation 
(for example Hahn et al., 1986 and Ellram & Carr, 1994). Competition between companies 
has thus extended to competition among supply chains (Li et al., 2006). 
 
Supply chain management (SCM) is a broad research field that holds many themes under it, 
such as collaboration, demand, logistics, strategic, supplier and marketing management (Soni 
& Kodali, 2013). Research on SCM has been fragmented and as there is no generally 
accepted definition for the term, the term has been used in many different contexts (Storey et 
al., 2006; Grimm et al., 2015). It has originated within the manufacturing industry and 
contributed to some well-known concepts, such as total quality management, lean 
management and just-in time management (Burgess et al., 2006). Nowadays SCM research 
addresses also areas outside the traditional manufacturing industry, including the service 
industry and virtual enterprises (Grimm et al., 2015). 
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SCM research borrows from many other research fields: Croom et al. (2000) identified 11 
different subject literatures that have contributed to SCM, such as purchasing and supply, 
organizational behavior, contingency theory, institutional theory, strategic management and 
network literature. Some other tightly linked research fields also borrow from SCM literature, 
including supply chain risk management (SCRM) and sustainable supply chain management 
(SSCM), that will be addressed separately in later chapters. This literature review will mainly 
concentrate on the supplier management aspect of SCM theory, but it should be noted that 
this grouping is only directional as boundaries between the different SCM areas remain loose 
and many of them are interrelated. 
 
2.1 Supplier management 
Supplier management includes many sub-themes such as supplier selection, supplier 
evaluation, supplier relationship management and supplier development. Besides SCM, it 
also owes to purchasing management and performance management disciplines. This chapter 
will concentrate on the problem of supplier selection, qualification and evaluation (SSQE). 
 
The process of selecting, qualifying and evaluating suppliers has attracted a lot of attention 
from modelling discipline, and there are many articles presenting complex algorithms and 
mathematical models for managing this process (for example Hammami et al., 2014 and 
Yadav & Sharma, 2016). A bit surprisingly, there are not many qualitative studies on this 
process and literature is lacking clear qualitative models for SSQE (Luzzini et al., 2014), 
even though its importance to organizations’ performance is well acknowledged (Carr & 
Pearson, 1999 and Kannan & Tan, 2000). 
 
In their book Purchasing and Supply Management, Johnson & Flynn (2015) divide the 
supplier selection criteria into three different levels: strategic, traditional and current 
additional. These levels and the criteria under them are summarized in Table 2.1.  
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Table 2.1: supplier selection criteria (based on Johnson & Flynn, 2015) 
Level 1: strategic 
Linking sourcing with strategy Assessing which suppliers are able to meet 
organization’s (strategic) requirements 
Risk assessment Assessing supplier risk versus expected returns 
Strategy development Developing purchasing strategy based on the risk 
assessment 
Level 2: traditional 
Technical, engineering, 
manufacturing and logistic 
strengths 
Evaluating supplier’s current and future operational 
strengths, including quality aspects 
Service design, operations and 
delivery 
Evaluating supplier’s current and future service 
capabilities 
Management and financial 
evaluation 
Evaluating supplier’s managerial systems and 
financial aspects in terms of price negotiations and 
financial health 
Level 3: current additional 
Financial considerations Evaluating means to strengthening purchasing 
organization’s financial aspects, such as tax savings 
Environmental impact Assessing sustainability aspects 
Innovation Assessing supplier’s potential for innovation 
Regulatory compliance Assessing supplier’s regulatory compliance 
Social and political factors Assessing social and political concerns related to 
the supplier 
 
From the three levels introduced by Johnson & Flynn (2015), strategic level criteria 
concentrate on how a supplier candidate would support company’s strategy, identify risks on 
this area and how company’s purchasing strategy with this candidate should be aligned. 
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Traditional level criteria concentrate on supplier candidate’s operational level strengths and 
weaknesses as well as management and financial aspects.  Finally, current additional level 
criteria address different areas that have arisen more recently into focus in supplier evaluation 
and include for instance supplier’s potential for innovation, environmental and societal 
factors and regulatory compliance. The writers emphasize, that the resources, time and 
attention invested to the process should reflect strategical importance and value of the 
purchase. 
 
According to study conducted by Luzzini et al. (2014), supplier evaluation process can be 
allocated into six main stages and furthermore assembled into three main processes that are 
presented in Table 2.2. Even though the purchasing unit is usually in the focal point and 
managing the SSQE process, other units, such as quality, engineering and finance, usually 
take part in the design and implementation of SSQE system and its different stages (Luzzini 
et al., 2014). 
 
In pre-qualification stage, an organization gathers preliminary information about the supplier 
firm. Potential suppliers may be dropped from the process during each of the stages. First 
stage is RfO, or request for offer, which in addition to collecting the first economic offer, 
serves also as a tool to receiving general information from the supplier. RfO is usually 
followed by a separate questionnaire to assess the supplier in more detail. If not already 
included in the first questionnaire, it is followed by a second one focusing on the specific 
product or service offered, concentrating on supplier’s technical and operational capabilities 
in relation to producing the service or product. 
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Table 2.2 supplier evaluation process steps (based on Luzzini et al., 2014) 
Pre-qualification “Collection of preliminary and general information about the 
supplier firm” 
RfO Economic offer from the product or service and gathering general 
information from the supplier 
Questionnaire(s) Gathering supplier-related information 
Product & process 
quality 
Gathering information on supplier’s capabilities to produce the 
product or service 
Qualification / 
Selection 
“Collection of in-depth information about the supplier product 
or service” 
Technical & 
economic 
Assessing supplier’s product and process quality 
Negotiation & 
budget split 
Further negotiations and assigning the supplier a share of the 
company’s total purchase volume 
Vendor rating “Comprehensive and continuous evaluation of supplier 
performance in terms of products and services delivered” 
 
If all the pre-qualification steps are passed, supplier enters the actual qualification/selection 
process, starting with assessing supplier’s product and process quality that may include (but 
not limited to) product sampling, on-site visits or initial discussions on contractual 
arrangements. If the supplier passes this phase, it formally enters the organization’s supplier 
base, which may be followed by further negotiations and assigning a certain share of 
organization’s total purchases. 
 
The final stage, vendor rating, concentrates on active suppliers that are assessed through 
different key performance indicators. According to Luzzini et al. (2014), typical focus areas 
are quality, service level and documentation. The purpose of this assessment is to identify 
the top-performing suppliers and, on the other hand, suppliers with many problems, and take 
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actions accordingly (such as preferring the top suppliers or implementing improvement 
plants for poor suppliers). 
 
Luzzini et al. (2014) emphasize that the SSQE process is always case-specific, and the 
indicators and metrics used should be adjusted to firm’s strategy and on the nature of product 
or service being procured. This is addressed by a process presented by Kraljic (1983), who 
defines a four-step process for strategically managing company’s supply: (1) classifying 
purchased materials according to their impact to profit and supply risk, (2) conducting market 
analysis regarding the relative power of the customer in regards of its individual suppliers, 
(3) positioning strategic materials identified in the first step in a matrix of supplier versus 
company relative power and (4), depending on where the material lies in the matrix, 
implementing a specific supply strategy (exploit, balance or diversify). Besides concentrating 
on the individual products or services procured, companies should also review the entire 
supply profile of their individual suppliers, differentiating long-term strategic suppliers from 
short-term non-critical suppliers (Luzzini et al., 2014). 
 
2.2 Supply chain risk management 
Supply chain risk management (SCRM) is not itself a new practice, as risks have existed also 
in traditional, local and integrated, supply chains (Tang, 2006a). However, as the traditional 
supply chains have shifted into more modern, global and outsourced supply networks, and 
the magnitude key suppliers grown significantly, the nature and severity of supply chain risks 
has risen significantly. Many articles refer to the time of turn of millennium as the big turning 
point in SCRM research, as many severe and global supply chain disruptions occurred (for 
example Ho et al., 2015; Sodhi et al., 2012; Tang, 2006a). One of the most known of these 
incidences is the fire at one of Ericsson’s main supplier in 2000 (a semiconductor plant owned 
by Phillips), that eventually was evaluated to have caused a $400 million loss for Ericsson 
(Chopra & Sodhi, 2004). Other examples include Dole’s banana plantation destruction by a 
hurricane in 1998 (Biddles, 1998), Dell’s recall of 4 million laptops due to defective battery 
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caused fire hazard in 2006 (Lawton & Dade, 2006) and Mattel’s recall of 19 million toys due 
to lead paint and loose magnets in 2007 (Story & Barboza, 2007).  
 
From a theoretical perspective, SCRM overlaps with SCM in many respects, but these two 
research fields should not be confused with each other. As was true with SCM, also SCRM 
lacks a clearly defined and broadly accepted definition (Diehl & Spinler, 2013), which makes 
locating it on a theoretical map also challenging. Drawing on the previous definitions of other 
writers, Ho et al. propose SCRM to be defined as “an inter-organisational collaborative 
endeavor utilizing quantitative and qualitative risk management methodologies to identify, 
evaluate, mitigate and monitor unexpected macro and micro level events or conditions, which 
might adversely impact any part of a supply chain”. Even though over-simplifying these two 
fields, the main difference could in a very general level between SCM and SCRM be 
considered as follows: SCM concentrates on making the supply chain more innovative, 
productive and effective, whereas SCRM focuses on identifying, preventing and managing 
risks laying in the supply chain. As with SSQE, the focus in SCRM research has been more 
on quantitative models than qualitative research. 
 
Risk management process in the supply chain context can be considered to consist of three 
different phases, containing six distinct steps, as suggested by Tummala & Schoenherr (2011) 
and presented in Figure 2.1. In phase I, all the relevant risks are identified, measurement of 
the severity of effects of the individual identified risks should they occur and assessment of 
the probability of the individual risk occurrence. On phase II, the individual risks are first 
evaluated based in their severity and probability and, at least for risk that are not on an 
acceptable level based on the evaluation, a risk mitigation plan is developed and implemented 
to manage the non-acceptable risk. The final in phase III focuses on monitoring the individual 
risks as well as the risk portfolio and the implementation and effectiveness of mitigation 
plans. 
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Perhaps one of the best overview of different risk categories in the supply chain is captured 
by Ho et al. (2015), whose illustration is presented in Figure 2.2. Based on their view, on a 
broader level the risks can be divided into macro- and micro-level (also catastrophic and 
operational (Sodhi et al., 2012) or disruption and operational (Tang, 2006a)) risks. As 
described by Ho et al. (2015), macro-level risks are rather uncommon, external occurrences 
that can have a devastating impact on companies and can be divided further into natural and 
man-made risks, such as earthquakes or hurricanes and war or political tremor. Micro risks, 
on the other hand, “refer to relatively recurrent events originated directly from internal 
activities of companies and/or relationships with partners in the entire supply chain”, and 
can be further divided into demand risks, manufacturing risks, supply risks and infrastructural 
(information technology, transportation and financial systems) risks. For the purpose of this 
thesis, the remainder of this chapter will focus on qualitative SCRM strategies of macro-level 
and supply risks. 
 
 
 
 
 
 
Figure 2.1: risk management process (adapted from Tummala & Schoenherr, 2011) 
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As companies have been racing to make their supply chains more efficient (or high-speed 
and low-cost) with initiatives such as just-in-time, the vulnerability of these supply chains to 
disruptions has grown significantly (Lee, 2004). Besides reducing costs and improve 
customer satisfaction in normal conditions, supply chain strategies should thus be able to 
secure company’s operations, should a major disruption occur. Tang (2006b) introduces nine 
different strategies for this purpose that are listed in Table 2.3. Tang (2006b) emphasizes, 
that these strategies have three main challenges: balancing between the costs and benefits of 
a specific strategy, fitting the supply chain strategy to company overall strategy and being 
able to proactively implement a given strategy or being able to identify the need of a given 
strategy in the first place. Even though same strategies may be applicable to mitigate also 
supply risks, the different nature between these two risk categories calls for specific means 
for supply risk management. 
 
 
 
Figure 2.2: conceptual framework of supply chain risks and risk management steps 
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Table 2.3 strategies for overcoming macro risks (adapted from Tang, 2006b) 
Strategy Description Benefit 
Postponement Apply product standardization and 
delay the point of product 
differentiation 
Enables a firm to change the 
configurations of different 
products quickly 
Strategic stock Maintain a stock of critical 
components or products in strategic 
locations 
Enables a firm to respond to 
market demand quickly 
during a major disruption 
Flexible supply 
base 
Maintain multiple suppliers Enables a firm to shift 
production among suppliers 
promptly 
Make-and-buy Maintain the capability to 
manufacture critical components or 
products in-house while outsourcing 
Enables a firm to shift 
production between in-house 
production facility and 
suppliers rapidly 
Economic 
supply 
incentives 
Provide economic incentives to 
suppliers for preventing perishment of 
supplier base 
Enables a firm to adjust order 
quantities quickly 
Flexible 
transportation 
Enhance multi-modal (air, road and 
water), multi-carrier and multiple 
route transportation 
Enables a firm to change the 
mode of transportation 
rapidly 
Revenue 
management 
Apply dynamic pricing and 
promotion when selling perishable 
products or services 
Enables a firm to influence 
the customer product 
selection dynamically 
Dynamic 
assortment 
planning 
Enhance assortment planning by 
promoting (displaying) widely 
available products or services over 
the ones facing supply disruptions 
Enables a firm to influence 
the demands of different 
products quickly 
Silent product 
rollover 
Introduce new products to markets 
without a formal announcement 
Enables a firm to manage the 
demands of different 
products swiftly 
 
Supply risks mean any adverse events or situations with the upstream partner of a company, 
that may have a negative impact on the company (Zsidis, 2003). Examples of supply risks 
include poor quality, uncertain capacity, late delivery, lack of supplier involvement and 
supplier failure in terms that the product is not delivered (Ha et al., 2015). They are in general 
considered more day-to-day level and not as significant as macro-level risks, but may 
nevertheless have a notable impact on company’s performance. Table 2.4 summarizes 
different supply risk approaches presented in the literature. 
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Table 2.4 strategies for overcoming supply risks 
Strategy Description 
Behavior-based 
management 
techniques (Zsidis & 
Ellaram, 2003) 
Focuses on supplier processes rather than outcomes; evaluate 
suppliers based on their behavior, which will have an effect on 
the outcome. Requires improved information sharing, 
monitoring supplier progress and actions and close relationship 
with suppliers 
Supplier certification 
Certificate suppliers that consistently meet predetermined 
quality, cost, delivery, financial and volume targets. Helps to 
reduce time-consuming controls of certified suppliers, generates 
information on supplier performance and aligns supplier’s 
behavior with the company’s processes 
Quality management 
program 
Establish a quality management program in supplier’s premises 
to achieve company’s quality requirements and expectations. 
Target costing 
Establish two-way information sharing and negotiation by 
sharing company’s sales estimates and production schedule and 
supplier’s cost structure and cost drivers and pursue together 
ways of reducing costs 
Supplier development 
Improve supplier’s performance and capabilities by for example 
developing supplier’s technical quality or delivery capabilities 
and driving continuous improvement. May include giving 
feedback to and training the supplier, sending company’s own 
employees to supplier’s premises and investing to the supplier’s 
facilities and equipment. 
Early supplier 
involvement (Zsidis 
& Smith, 2005) 
Involve supplier already in an early phase of product 
development to reduce the risk of supplier failure, quality 
problems, supplier insolvency, product delays etc. 
Reducing supply 
chain complexity 
(Choi & Krause, 
2006) 
Carefully manage the (1) number of suppliers, (2) differentiation 
of suppliers including cross-border barriers, technical 
capabilities and operational practices and (3) inter-relationship 
among suppliers to reduce supply risks arising from supply 
chain complexity. Reducing supply base to an extreme, on the 
other hand, will also increase supply risk significantly. 
Contingency 
planning 
(Colicciha et al., 
2010) 
Develop plans and actions for alternative modes of supply to be 
activated in case a negative event occurs for secure supply. 
 
Even though a lot of literature exists around SCRM, many gaps and unexplored topics 
remain, starting with the fact that a clear definition of SCRM is still to be acknowledged.  As 
SCRM itself contains such a broad variety of topics and different types of risks, it is 
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challenging to get a holistic view of overall risk management practices instead of 
concentrating on individual risk types. From practical point of view, even though many 
conceptual frameworks have been presented, empirical research is still abundant in many 
respects and many theories are still to be tested in practice. Finally, the lack of qualitative 
research and “easy-to-approach” SCRM, instead of complicated modelling applications, 
makes it harder for real-life organizations to apply research to real-life conditions. 
 
3. SUSTAINABILITY AND SUPPLY CHAIN MANAGEMENT 
Importance of and attention on sustainability has grown as supply chains have become more 
and more global. Globalization has strongly affected production and consumption patterns 
on every industrial aspect and will continue to do so in the future. Typical feature of today’s 
supply chain is to organize higher-skill activities, such as product design, marketing and 
business development, in developed countries, while locating lower-skill manufacturing 
activities to developing countries. It is also common for brand-owning companies to 
outsource the manufacturing activities. This division between higher-skill activities and 
manufacturing operations creates concerns that the social, environmental and economical 
norms that are expected in company’s home country are not appropriately enforced in the 
countries where manufacturing is taking place.  
 
Globalization, rising importance of supply chains, increased competition, harsher regulations 
and intensifying scarcity of resources have alone made companies to pay more attention on 
sustainability (Walker et al., 2008). Besides these drivers, many different NGOs have shifted 
their focus, or even born, to govern sustainability of modern global supply chains.  
Furthermore, companies experience pressure towards managing supply chain sustainability 
from their customers, other firms, governments and even local communities. Governance for 
sustainability is thus multifold, not something stipulated solely by government agencies, but 
by several different types of actors with many different instruments. Besides the rising 
strategic importance of SCM and the purchasing in a traditional sense focusing at lower costs, 
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quality and flexibility, the growing importance of sustainability demands buyers to do this in 
a social and environmental manner.  This setting has evoked rich literature around 
sustainability and supply chain management. The purpose of this literature review is not to 
capture a holistic view on theories of sustainability management in supply chains, but to 
introduce the main points of relevance to the theme under study.  
 
3.1 Basic terms: GSCM, triple bottom line & SSCM  
The basis of sustainability management in supply chains started to evolve from 
environmental aspects in the early 1990s, first focusing on specific activities of SCM such as 
logistics and purchasing, and then integrating these activities to achieve environmental 
effectiveness, eventually establishing the term of green supply chain management, GSCM 
(Sarkis et al., 2011). As described by Beamon (1999), GSCM focuses on minimizing 
environmental impacts of a product through its entire life cycle as an extension to traditional 
SCM. Sustainable supply chain management, SSCM, is another established term that is in 
many respects viewed as an extension of GSCM incorporating the other, social and 
economic, aspects of sustainability (Ahi & Searcy, 2013).  
 
One widely used framework used in conceptualizing SSCM is the triple bottom line – or the 
three dimensions of sustainability – that was introduced by Elkington in 1998. According to 
Elkington (1998), sustainability of organizations at a broad level consists of three 
components: the natural environment, society and economic performance. Perhaps the most 
important notion of the triple bottom line is that sustainability is not something that 
organizations can be profitable in spite of sustainability, but that companies increase their 
profitability by engaging environmental and social activities that improve their economic 
performance (Carter & Rogers, 2008). The triple bottom line framework is presented in 
Figure 3.1. 
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In their effort to include different characteristics found in the literature, Ahi & Searcy (2013) 
defined SSCM as “the creation of coordinated supply chains through the voluntary 
integration of economic, environmental, and social considerations with key inter-
organizational business systems designed to efficiently and effectively manage the material, 
information, and capital flows associated with the procurement, production, and distribution 
of products or services in order to meet stakeholder requirements and improve the 
profitability, competitiveness, and resilience of the organization over the short- and long-
term”. As GSCM and SSCM are based on the same principles, only with the difference of 
GSCM omitting the social and economic dimensions of sustainability, this chapter will use 
the term SSCM with the notion that it also withholds GSCM and that the literature of GSCM 
in a broad sense also applies to SSCM. When placing SSCM on a theoretical map, it is 
obvious that it has the same linkages to and builds on the same theories as SCM. However, 
SSCM literature has also specifically been linked to several organizational theories by Sarkis 
et al. (2011), including for example the complexity theory, resource based view, institutional 
theory and stakeholder theory.  
   
Figure 3.1: the triple bottom line (adapted from Carter & Rogers, 2008) 
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3.2 Sustainable supply chain management 
Even though SSCM refers to the whole supply chain, the literature has usually had its main 
focus in supplier management practices (Beske & Seuring, 2014). SSCM frameworks tend 
to rely on a typical SCM orientation that begins from a focal company as an initiator of 
sustainable practices, which typically has the most power and influence along the supply 
chain and extends its requirements for sustainable practices to its suppliers (Gimenez & 
Tachizawa, 2012; Miemczyk et al., 2012). This is also the orientation for SSCM framework 
introduced by Beske & Seuring (2014), which aims to describe SSCM “in or through SCM”.  
 
Beske & Seuring (2014) identify five different key categories and prevalent practices under 
them from SSCM literature. The practices in this framework should be understood as a way 
of doing things with the aim of improved performance and the categories as a way of dividing 
and grouping practices under different umbrellas. The five categories are orientation, 
continuity, collaboration, risk management and pro-activity. These categories are further 
divided into three underlying drivers: strategic values, structure and processes. The 
framework is illustrated in Figure 3.2. Each of the five categories and related practices are 
introduced below.  
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.2: Key categories and related practices in SSCM (adapted from Beske & Seuring, 2014) 
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The first category Beske’s & Seuring’s (2014) framework, orientation, addresses company’s 
strategic orientation and values: to reach effective SSCM, strategy and top management are 
obliged to encourage sustainability and supply chain management in the first place. 
Sustainability has to be integrated to company’s strategy and receive top-management 
support for reaching the full potential of SSCM. Sustainability-oriented companies are 
usually giving equal weight to all three (economic, environmental and societal) dimensions 
of sustainability in their decision-making, thus following the triple bottom line practice. 
Different sustainability goals may conflict with each other and it is important to recognize 
possible trade-offs between the triple bottom line dimensions. Second practice in this 
category is SCM, which implicates that traditional SCM practices have to be integrated to 
the strategy and decision making and also calls for top-management support. This category 
thus includes conventional supply chain thinking through SCM practices, but is separated 
from it by including the triple bottom line dimensions in the strategic prerequisite. 
Orientation category can be seen as the starting point and precondition for encaging SSCM 
and is built upon strategic values. 
 
Continuity category can be viewed through structural decisions: it defines how the supply 
chain is set up and how different partners work together. As Beske & Seuring (2014) describe 
it, continuity underscores mutual and beneficial relationship between the supply chain 
partners and reflects performance of the entire supply chain, instead of performance of its 
individual members. In addition, the writers furthermore mention that continuity is about 
sharing risks and profits along the supply chain. Practices under this category concern 
building long-term relationship, development of supply chain partners and selection of 
(qualified) partners. Long-term relationship helps to build trust, common goals and 
structures, whereas partner development aims at improving performance and capabilities of 
the supply chain (Beske & Seuring, 2014). Supplier selection is described to include, besides 
selecting the right partners, reducing the supplier base to a limited number of suppliers. 
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Beske’s & Seuring’s (2014) third category, collaboration, is staged between structure and 
processes: it is defined to be about generating collaboration in the first place (structure), but 
also about how collaboration is achieved in the operational level in practice. Beske & Seuring 
(2014) describe collaboration to go one step further than cooperation, for example in forms 
of inter-organizational learning and long-term orientation. Practices in the category include 
logistic and technological integration, enhanced communication along the entire supply chain 
and joint development of capabilities and products. 
 
In general, SSCM is perceived to have different and perhaps even higher risks than the 
traditional SCM, including significant disruption risk due to a smaller supplier base and 
reputational risks; on the other hand, supplier base reduction and increased collaboration with 
the remaining suppliers are thought to reduce risks through lower supply chain complexity 
and uncertainty (Miemczyk et al., 2012). In Beske’s & Seuring’s (2014) framework, risk 
management category is placed in the processes stage and is about reducing the many risks 
of SSCM. Practices introduced by Beske & Seuring (2014) are selective monitoring through 
for example audits of an individual partner, standards and certifications that are usually more 
general and concern several companies, and finally, managing the many sustainability 
pressure groups, such as NGOs and local authorities. 
 
The final category of Beske & Seuring (2014), pro-activity, integrates sustainability to 
product development phase, through product life cycle assessment and initial supplier 
selection. This also concerns involving a wider group of stakeholders to company operations 
and is about acquiring knowledge and learning from these stakeholders, leading to 
sustainable innovations. These practices are mainly driven by company processes. 
 
What is, then, the difference between SSCM and conventional SCM? SSCM is commonly 
seen to be developed from the theories and practices of SCM for the demands of sustainability 
(Svensson, 2007). From the practices introduced by Beske & Seuring (2014), the writers list 
the triple bottom line, stakeholder management and life cycle assessment to be exclusive to 
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SSCM and to bring out significant differences in standards and certification, communication, 
technological integration and partner selection practices. 
 
3.3 Dynamic capabilities in SSCM 
The SSCM framework presented above can be seen as rigid and may not be sufficient in 
describing SSCM in a dynamic environment. Organizations pursuing a sustainability strategy 
or acting in sustainability-sensitive industries can also in general be seen to be more prone to 
unpredictable changes than other companies.  This chapter has already linked SSCM to 
resource based view that, according to Teece et al. (1997), in a rapidly changing and 
unpredictable environment is unable to adequately explain competitive advantage of some 
firms in relation to others. In dynamic markets with rapidly changing competitive 
environment, long-term competitive advantage can only be achieved with dynamic 
capabilities, where companies “integrate, build and reconfigure internal and external 
competencies to address rapidly changing environments” (Teece et al., 1997). Dynamic 
capabilities are thus about adapting to fast and unpredictable changes, risk and opportunities 
and shaping company’s environment to achieve competitive advantage. This is also reflected 
in the definition of dynamic capabilities by Eisenhardt & Martin (2000): “The firm’s 
processes that use resources—specifically the processes to integrate, reconfigure, gain and 
release resources—to match and even create market change. Dynamic capabilities thus are 
the organizational and strategic routines by which firms achieve new resource 
configurations as markets emerge, collide, split, evolve, and die.” 
 
Drawing from the literature, Beske (2012) introduces linkages between SSCM and dynamic 
capability theories in a conceptual level. He identifies some of the major overlapping 
business environment characteristics to lie in globalized markets, market transparency, 
market demand, product success and performance; these linkages are highlighted in Table 
3.1.  
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Beske (2012) identifies five distinctive categories of dynamic capabilities to be of particular 
importance in SSCM.  Figure 3.3 presents these categories as part of a SSCM framework 
first introduced by Beske (2012) and further modified by Beske et al. (2014). In this 
framework, dynamic capabilities are thought to enable efficient use of static capabilities and 
create new ways of using existing as well as totally new capabilities. Long-term competitive 
advantage does thus not arise from holding resources, but from the ability to configure and 
re-configure these resources (Teece et al., 1997; Eisenhardt & Martin, 2000). Next, the five 
categories of dynamic capabilities are introduced. 
Table 3.1 major overlaps between dynamic capabilities and SSCM theories  
(adapted from Beske, 2012) 
Business 
environment 
characteristics 
Dynamic capabilities SSCM 
Globalized markets  
Dispersion of the geographical 
and organizational sources of 
innovation and manufacturing 
Dispersion of the 
geographical and 
organizational sources of 
innovation and manufacturing 
Market 
transparency  
Market boundaries are blurred  
Sometimes intransparent 
buyer-supplier relationships; 
tacit knowledge and contacts 
Market demand  
Market demand changes are 
nonlinear and unpredictable 
Mature, informed customers, 
instant information sharing; 
rapidly, dynamically and 
unpredictably changing 
demands 
from stakeholders 
Product success  
 
Product success often based on 
multiple technologies and 
companies 
Product success dependent on 
different technologies and 
companies 
Performance 
Competitive advantage is more 
than just financial performance 
Firm performance measured 
on 
three dimensions of 
sustainability 
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Knowledge assessment category is described by Beske (2012) to comprise of capabilities to 
access, acquire, understand and share knowledge of the supply chain partners. This category 
is important as gathering and creating new knowledge and is presented to be essential in 
maintaining competitive advantage in dynamic markets by Beske (2012) 
 
Supply chain partner development is about developing all the actors in a supply chain, which 
can include customers, to realize their purpose in the supply chain (Beske, 2012). The 
different actors of a supply chain thus develop each other, and development becomes a 
continuous routine. 
 
As developing partners to be better partners is considered important, so is the ability to co-
evolve, or to develop and implement new competences for the supply chain. Co-evolving 
category includes dynamic capabilities that enable different actors to combine their resources 
to create new synergistic capabilities (Beske, 2012). 
 
Reflexive supply chain control is defined by Beske (2012) as sharing, evaluating and 
influencing the actions taken by individual supply chain actors to reflect the benefit of the 
whole chain and, on the other hand, to evaluate the prevailing practices against changes in 
the prevailing business environment and adapt to these changes. This category is thus about 
influencing other actors in the supply chain to implement a common strategy and to adapt it 
as needed.  
 
Finally, supply chain re-conceptualization is described by Beske (2012) as considering a 
wider set of stakeholders, such as NGOs, as part of, and integrating them to, the SSCM. This 
category builds upon stakeholder theory that has been introduced in the earlier sections. 
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Figure 3.3: framework of dynamic capabilities in SSCM  
(adapted from Beske, 2012 and Beske et al., 2014) 
The frameworks presented by Beske (2012) and Beske et al. (2014) are both relying solely 
on existing literature, thus the relationship between SSCM and dynamic capabilities is 
lacking empirical research and the explanatory and predictive value of these frameworks 
remain to be tested in real-life settings. Empirical studies may also prove some of the 
dynamic capabilities presented in the frameworks irrelevant for SSCM as well as add new 
ones yet to be discovered. It is quite obvious that to achieve competitive advantage through 
dynamic capabilities, supply chain has to be highly integrated among its individual parties 
and the basic principles of SSCM have to be in place.  
 
3.4 Sustainable supplier management 
Literature of SSCM exists in a broader level addressing the three dimensions of 
sustainability, but supplier management in general, and SSQE in particular, in regards of 
sustainability is not that well established (Zimmer et al., 2016). Figure 3.4 presents one of 
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the rare frameworks found in the literature of sustainable supplier management processes 
presented by Zimmer et al., 2016, that consists of three core processes: sustainable supplier 
selection, sustainable supplier development and sustainable monitoring. 
 
 
 
 
 
 
 
 
 
 
 
According to Zimmer et al. (2016), sustainable supplier selection process consists of 
identifying and evaluating supplier candidates in regards of the triple bottom line dimensions, 
the defined criteria serving also the base of evaluation in the monitoring and development 
processes. Sustainable supplier monitoring process is seen as a continuous evaluation of an 
existing supplier against defined minimum requirements and improvement in terms of the 
triple bottom line dimensions, and also serves as a trigger for supplier development or 
replacing a supplier in case it is not complying to the requirements. Finally, a supplier can be 
transferred to the sustainable supplier development process from supplier evaluation or 
monitoring processes. The scope of the three sustainable supplier development processes 
presented in Figure 3.4 are somewhat different: development during evaluation and 
qualification usually focuses on achieving established minimum requirements, whereas the 
other two development phases usually focus on improving the supplier beyond the minimum 
requirements. As explained by Zimmer et al. (2016), sustainable supplier selection, 
Figure 3.4: sustainable supplier management processes (adapted from Zimmer et al., 2016) 
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monitoring and development processes are seen as independent, but interrelated, of each 
other. 
 
The framework presented by Zimmer et al. is a very generic one, and is differentiated from 
the traditional supplier management only by the focus on sustainability: the core processes 
and principles are the same. Furthermore, it doesn’t describe the meta-processes and actual 
means of how companies in practice manage the sustainability aspect of their suppliers. The 
lack of prescriptive sustainable supplier management frameworks shows that the SSQE 
process in terms of sustainability is not well established in the literature. As with traditional 
supplier management, there are quantitative algorithm-based models for evaluating supplier 
sustainability through different parameters, but qualitative methods are virtually nonexistent 
in the literature. Next, this chapter will examine supply chain sustainability from risk 
management point of view. 
 
3.5 Supply chain sustainability risk management 
One of the rare hands-on frameworks for supply chain sustainability risk management is 
given by Foerstl et al. (2010), based on their own study in chemical industry (see Figure 3.5). 
It includes six different stages: external responsiveness, supplier sustainability risk 
identification, assessment of supplier sustainability risk, supplier sustainability risk 
consequences, sustainability risk management response and sustainability risk performance 
outcomes. As managing external stakeholders such as NGOs has been already discussed 
above, this chapter will concentrate on the five latter stages. 
Figure 3.5: supply chain sustainability risk management (adapted from Foerstl et al. 2010) 
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According to the study of Foerstl et al. (2010), purchasing and supply managers experience 
significant external pressure in terms of supply chain sustainability, primarily from 
regulatory bodies. This pressure can be in the social or ecological dimension of sustainability, 
and companies focus on the dimension(s) for which they experience pressure. The identified 
risk areas thus depend on what kind of external pressure companies experience. Foerstl et al. 
(2010) also conclude, that even though the sustainability dimensions under focus may alter 
between companies, the processes and techniques of risk assessment are similar. The reason 
of limiting risk assessment to mainly one of sustainability dimensions was found to be 
shortage of internal resources. Similarly, suppliers that are seen to impose the biggest risk 
are given high priority in the sustainability risk management processes. 
 
As presented in the earlier chapters, risk assessment is typically conducted through two 
components: assessing the consequences (impact) of an event, and the probability 
(likelihood) for the event to occur (Manuj & Mentzer, 2008). In their study, Foerstl et al. 
(2010) found that the impact-likelihood method is prevalent risk assessment method among 
the interviewed chemical companies. The companies initially relied on the information 
available in their supplier database and the probability of occurrence was evaluated through 
four indicators: physical properties of the supplied product, production process, supplier’s 
geographical location and supplier’s past performance records. Assessment of these 
indicators is done qualitatively and different indicators can be given different weights, 
depending on the product category. The consequences of a non-compliance were found to be 
estimated through indicators such as purchasing volume and strategic status of the supplier.   
 
Based on these two components, suppliers were positioned to a two-dimensional matrix and 
the subsequent action depends on the supplier’s position in the matrix. Non-critical suppliers 
were managed through a self-declaration on sustainability compliance, whereas critical 
suppliers are managed through self-assessment questionnaire and audited in case there is 
doubt about sustainability practices. Very critical suppliers are audited automatically. New 
suppliers taken to the selection process are evaluated through a self-assessment questionnaire 
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and chosen suppliers have to pass an on-site audit to be considered as potential suppliers for 
the company. 
 
The probability-impact risk assessment method has been criticized to be static in it nature 
and thus to be limited on continuous supplier sustainability risk monitoring (Gelderman & 
Weele, 2003). Even though this was acknowledged by the companies following the method, 
the probability-impact risk assessment was seen as an easy tool for determining subsequent 
sustainability risk mitigation strategies and identifying supplier development needs (Foerstl 
et al., 2010). 
 
The risk assessment is followed by decision of supplier consequences and risk mitigation 
processes. Foerstl et al. (2010) conclude, that for established suppliers, the preferred action 
in case of violations is to retain the supplier through supplier development. Here, the supplier 
sustainability criteria are seen as dependent assessment criteria and violations usually result 
in increased resource allocation from the buying firm. On the contrary, in case of new 
suppliers, deficiencies in sustainability compliance may easily result in elimination of the 
supplier from the supplier selection process. Here, sustainability criteria are seen as 
independent selection criteria that are important in screening new suppliers and preventing 
high-sustainability risk suppliers from entering the supply base. 
 
As described in the framework introduced by Foerstl et al. (2010), sustainability risk 
assessment divides suppliers into a continuum with insignificant risk in the other end and 
critical risk supplier on the other. Firms have basically three options to reduce the observed 
risks among their supplier: ignoring high-risk suppliers when selecting new ones, developing 
established suppliers above acceptable standards and termination of supplier relationship 
(phase-out) of an existing supplier. First option is quite straight-forward and is dependent on 
the efficiency of supplier selection process. It prevents reputational damage brought by new 
non-compliant suppliers. Second option reduces risks among suppliers as well, but 
additionally broadens the available supplier base and builds the relationship with suppliers. 
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It also enhances cross-functional and inter-firm collaboration and thus may have operational 
performance implications. Third option, terminating supplier relationship, is perhaps the 
most radical one and usually leads to a moral obligation of the buying firm to implement 
corrective actions that may be time- and resource taking. It may also mean publicly 
acknowledging a supply chain misconduct that brings negative publicity for the company.  
 
Supply chain sustainability risk management is thus as much about choosing the right 
suppliers as it is about neglecting the ones posing high risks. Not every supplier can be 
considered as a strategic partner, and those that are must be screened carefully. Integration 
towards sustainability and achieving competitive advantage through SSCM practices (or 
dynamic capabilities) is not possible if company has chosen wrong partners. It is for example 
impossible to reach sustainable supply chain if other parties in the chain don’t even see the 
importance of sustainability, nor does it make sense to assign a lot of resources into supplier 
development if the supplier is not willing to develop. 
 
3.6 Challenges in supply chain sustainability management 
Enhancing and managing sustainability in supply chains is by far not an easy task and poses 
some specific challenges. According to Boström et al. (2015), global supply chains and 
networks experience six different kind of challenges (or gaps) in governing their 
sustainability: geographical, informational & knowledge, communication, compliance, 
power and legitimacy challenges. These challenges are listed in Table 3.2 and will be further 
discussed below. 
 
Geographical gaps arise from the distance between the different parties in a global supply 
chain. This remoteness brings “a distance from the many serious environmental and social 
impacts of production, which help to contribute to public ignorance towards these 
circumstances and make public debate and opinion-formation difficult” (Boström et al. 
2015). In other words, it is easier to ignore sustainability violations that occur on the other 
side of the world than the ones that occur in your proximity. Chkanikova & Lehner (2015)  
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Table 3.2 challenges in governing sustainability in global supply chains  
(based on Boström et al., 2015) 
Challenge Description/cause Recommendation 
Geographical 
Distance between different parties causes 
ignorance of sustainability violations  
Mediated 
communication  
 Using local 
suppliers 
 Generic standards 
Informational 
& knowledge 
Difficulty of getting reliable, 
comprehensive and credible information 
from the supplier, especially in case of 
long geographical distances 
Increasing transparency 
 Independent 
information 
providers 
 Verification 
agents 
Communication 
Challenge of finding communication 
tools, strategies and systems to overcome 
geographical and social distances 
Strengthening 
communication 
 Standards 
 Information 
systems  
 Direct interaction  
Compliance 
Difficulty of ensuring and governing 
supplier’s compliance to legislation and 
to the established sustainability standards 
Establishing effective 
governance practices 
 Effective audit 
program 
 Networking with 
external 
stakeholders 
(NGOs) 
Power 
Due to lack of relative power, buyers are 
unable to enforce standards and 
requirements on supplier, and/or suppliers 
are unable to contribute in shaping these 
standards 
Balancing power 
distribution along the 
supply chain 
Legitimacy 
Existing governance arrangements give 
legitimacy to inefficient standards, block 
innovation and favor and give power to 
certain stakeholders 
Critical evaluation of the 
efficiency of current 
governing practices 
 
propose favoring local suppliers and approaching them directly for simplifying supply chains 
and overcoming geographical challenges. As majority of supply chains will stay global, 
Boström et al. (2015) encourage using generic standards and other ways of mediating 
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communication. However, they also point out that several articles underline risks involved 
in using global generic standards without considering different cultural contexts. 
 
Geographical distances increase need for reliable, comprehensive, verified and credible 
information, which creates information and knowledge gaps. As shown by the study of 
Börjeson et al. (2014), getting such information can be extremely challenging and a big gap 
may exist in knowledge of buyer and supplier organizations.  The dilemma here that supply 
chains are facing is how to retrieve delicate information if this information will put the 
informant in bad light? Not all actors in the chain (producers, buyers, end-consumers, 
authorities) have the same information, which creates an information asymmetry that 
Boström et al. (2015) propose to be compensated using independent information providers, 
verification agents and other means for increasing transparency. Transparency, however, is 
not always straight-forward and there are pitfalls especially in constructing transparency in 
different societies as presented by Mol (2015): someone always decides what is kept secret 
and to whom information is revealed. Finally, Boström et al. (2015) stress that interpreting 
information received is seldom explicit and usually needs interaction between suppliers and 
buyers. 
 
As presented by Seuring & Muller (2008), the need for communication along the supply 
chain is argued heavily for in the SSCM literature, thus the third challenge introduced here 
is communication gaps. According to them, several articles bring out challenges in finding 
communication tools, strategies and systems to overcome geographical and social distances.  
As presented by Boström et al. (2015), communication may be strengthened with standards, 
information systems and direct interaction between parties, but is weakened by problems 
brought by language, trust, costs, unequal expertise and cultural codes. Increasing supply 
chain complexity emphasizes communication problems. 
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Deviances between recognized global sustainability standards and on-the-ground compliance 
generates compliance gaps: even global standards can remain neglected in practice as the 
tools for ensuring compliance are limited (Boström et al. 2015). As illustrated in the study of 
Helin & Babri (2015), compliance gaps may remain even if auditing systems are in place as 
violations can remain undetected and improvement may remain only marginal, even though 
there are also successful examples of implementing sustainability standards. 
 
Fifth identified challenge is power gaps, which on the other hand create problems for the 
buyers if they lack the power to enforce standards and requirements on supplier (Helin & 
Babri, 2015) and, on the other, create problems for suppliers to whom the lack of power 
means lack of flexibility and ability to contribute in shaping these standards (Vellema & 
Wijk, 2015). Boström et al. 2015 suggest that equal distribution of power among supply 
chain is crucial for creating sustainability. 
 
Finally, the article of Miller & Bush (2015) highlights that many global governance 
arrangements are continued, even though there is little evidence of improvement and much 
evidence on the flaws that actually prevent improvement. These arrangements have been 
unable to solve geographical, informational, communicative, compliance and power 
problems, and on the contrary create new gaps called legitimacy gaps by Boström e. al. 
(2015). These gaps occur when governance arrangements enable operation and authority of 
inefficient standards, block innovation, favor and give power to certain stakeholders and 
shape the markets. The efficiency and intends of governance arrangements should thus be 
critically evaluated. 
 
Boström et al. (2015) conclude that generic, global standards alone are not sufficient and that 
implementation of these standards should be done keeping local context in mind. To 
overcome the many supply chain management challenges, monitoring and enforcement 
methods need to be supplemented with education and other means and governance 
arrangements should be developed through reflexive learning. There is a significant need for 
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responsiveness in governing supply chains, and it should never be seen as a one-shot effort, 
but rather a long-term, collaborative reflective and committed process. 
 
4. RESEARCH METHODOLOGY  
This chapter discusses the research methods applied in this Master’s Thesis. First, I will 
introduce the research question and rationalize its relevance. After going through the research 
question and motivation behind it, the research approach used in this study is described. Next, 
the context of this research and the sample studied is introduced. This is followed by research 
design, or data collection and analysis. The chapter is concluded by discussion about the 
validity, reliability, generalizability and limitations of the study.  
  
4.1 Research question and its relevance  
The research question of this thesis is divided into three separate questions: 
What is the significance and nature of Good Manufacturing Practice compliance risk? 
How is supplier and risk management constructed in a highly regulated and enforced 
environment? 
What are the impacts that strong regulation and authority enforcement impose to supplier 
and risk management practices? 
Using pharmaceutical industry as the research context allows to study supplier and risk 
management in a very specific setting of high authority regulation and enforcement and the 
effects of these particularities. Furthermore, managing supply chain compliance in general 
remains an understudied field, the recent advancements being related to supply chain 
sustainability management. The purpose of the first question is to ensure relevance of the 
studied phenomenon to pharmaceutical companies in order to confirm that GMP-compliance 
risk is something that shapes their behavior. Another motive is to understand the prevalent 
conjectures around this phenomenon.  
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The second question addresses the process of establishing and maintaining supplier and risk 
management practices within the research context as it is necessary to establish the 
fundamental drivers of supply chain compliance management in the given setting. The final 
question leans to the results of the two previous ones and draws attention to the more 
generalizable impacts that regulations may have. 
 
Relevance of the research question can be seen from three different level. First, the 
pharmaceutical industry and its supply chain practices have not been well addressed in the 
literature even though their effect to the health of modern societies are significant 
(emphasized by many recent global drug shortages). This research adds to the current 
understanding of how pharmaceutical supply chains operate in the prevalent environment. 
Another societal consideration relates to the balance between industry self-regulation and 
authority regulation and the effects of emphasizing the latter one. From theoretical 
perspective, this research contributes to the existing qualitative literature of supply chain 
management in general and specifically to supplier and risk management and also has clear 
implications to sustainability management. 
 
4.2 Research approach  
Research methods can be understood as the methods used to answer the research question, 
and may also have an impact on producing it (Ghauri & Gronhaug, 2005). In upper level, 
research methods are divided into qualitative and quantitative methods, from which 
qualitative research is seen to highlight the fundamental understanding of and insights in to 
a certain phenomenon and thus being especially important for studies where only little is 
known about the subject (Marschan-Piekkari & Welch, 2004). This study explores a 
previously understudied topic of supply chain GMP-compliance and its core objective is to 
understand the current management practices. For these purposes, qualitative methods seem 
to be the most appropriate ones.  
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According to Ghauri & Gronhaug (2005), case study is an especially relevant method, if the 
research topic is hard to examine outside its natural setting. According to Yin (2003), case 
study method has been conventionally used when research tries to answer how- or why-
questions.  The research question presented above seems to build also from what-questions 
(what are the…; what is the…), but it is mainly due to the chosen wording of the question. 
The research question could easily be edited to include how-questions without changing its 
content: how do strong regulation and enforcement impact instead of what are the impacts, 
and how significant instead of what is the significance. In addition, the questions are studied 
in a very specific (but also complex) context of pharmaceutical supply chain. Based on these 
features, case study approach looks justifiable and is utilized in this research. 
 
Case studies are furthermore divided into single and multiple case studies, where multiple 
case studies are seen to give more compelling and robust results (Yin, 2003). In this study, 
the focus is on industry practices in general, rather than practices of a certain company, so 
multiple case study method is applied.  
  
Another division can be made between deductive and inductive approaches: deductive 
approach examines a theory arising from existing theory, whereas inductive approach aims 
to generate theory from empirical research (Saunders et al., 2000). Even though one could 
see the two approaches ruling each other out, they can also be complementary to each other 
(Bryman & Bell, 2003). This study has some deductive features: one objective is to find 
similarities to existing theoretical framework of sustainability management in supply chain 
context. Furthermore, interviews were planned on a thematic framework arising from 
sustainability management theory. However, the main focus is in framing a previously 
understudied phenomenon, supplier and risk management practices in a highly regulated and 
enforced environment, with only limited existing theory, making the study mainly inductive 
in its nature. Besides deductive and inductive approaches, also abductive approach can be 
used especially in cases where researcher aims to discover new things (new variables and 
new relationships; Dubois & Gadde, 2013). From the parts where this study addresses a new 
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actor, quality department, and a new sub-process of supply chain GMP-compliance 
management, and the relationship of these two variable to the traditional and theoretically 
established supply chain management, it can also be considered as abductive. 
 
4.3  Research design and conduction 
Research design is defined by Yin (2003) as “the logical sequence that connects empirical 
data to a study’s initial research questions and, ultimately, to its conclusions”. Research 
design is thus an integral part of any research and should thus be done carefully. The purpose 
of this section is to describe the decisions and steps made within the methodological 
framework built in the previous section, justify these decisions and explain occasions in 
which it was necessary to deviate from the initial outline. The section starts with specifying 
the micro-level research context and then moves to describing the research design process of 
this study, including choosing research sample, data collection methods and data analysis 
methods. 
 
 Research context  
As described above (chapter 1.1), the macro context of this thesis is pharmaceutical industry 
and external supply chain management. From the research topic, the context can be refined 
to GMP-compliance management within external supply chain management in the 
pharmaceutical industry. This study did not limit the scope to a certain geographic region, so 
in principle it concerns the whole global pharmaceutical industry, even though most of the 
cases included in the study are from Europe and not all major pharmaceutical regions are 
represented.  
  
Besides geographical division, two other ways to segment the pharmaceutical industry are 
seen important background information for the study: pharmaceutical companies can be 
divided into chemical and biochemical companies according to the nature of their products, 
or to proprietary companies developing, manufacturing and marketing their own products 
and contract manufacturing pharmaceutical companies selling manufacturing services to 
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other companies. Naturally, many of the companies have both chemical and biochemical 
products and manufacture both for their own purposes and for external parties, but usually 
one of the two features is where main business comes from. The cases studied in this research 
were all companies concentrating mainly to chemical pharmaceuticals. However, the cases 
included both proprietary and contract manufacturing companies.  
  
In the meso-context (here corresponding firm-level), supply chain management has 
traditionally been responsibility of procurement and quality assurance. Further, assuring 
compliance to GMP-standards, within internal and external supply chain, has conventionally 
been assigned solely to quality assurance. Supply chain GMP-compliance management in its 
simplest form has been managing frequent GMP-audits, their reporting and overseeing that 
audit observations have been met with acceptable corrective actions. Micro-level context, 
based on this responsibility division, is thus be defined as supply chain GMP-compliance 
management within the quality assurance department.   
  
Inside the company quality assurance, responsibility can further be placed to corporate level 
quality assurance, manufacturing site level quality assurance, or to both of them. This 
research targeted the corporate level quality assurance where it was relevant and accessible. 
In two of the six cases, the main responsibility of company supply chain GMP-compliance 
laid in the manufacturing site level quality assurance, and information was gathered from this 
level.   
  
 Research design and conducting the study 
This research followed the process presented in Table 5.1. This process was presented by 
Eisenhardt (1989) for “inducing theory using case studies” and is thus seen a good fit with 
the objectives of this study. In her article, Eisenhardt (1989) stresses that the process is highly 
iterative, meaning that the steps are not necessarily taken in the order presented, and that the 
researcher goes back-and-forth between the steps and realigns his/her assumptions and 
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previous work as new data comes in. Nothing is written in stone before the whole process is 
completed. 
Getting started: Researcher’s experience in the field made it possible to construct a 
preliminary research question based on what was known from the area and what was initially 
considered to be the main topics of interest and objectives to be addressed in the study. This 
preliminary research question helped to concentrate the efforts made in the next step into a 
certain area. It was kept in mind that the actual research question would arise from literature 
review, after revealing what had been already done and how could this study best contribute 
in creating new knowledge. 
Preliminary literature review: This review was performed to learn what had already been 
done in the field and find a specific focus area for the study. Supply chain management and 
supply chain risk management literature review revealed that this general theoretical 
background could not be directly applied due to the specific features of pharmaceutical 
industry and compliance management. Similarly, it was realized that supply chain 
management in pharmaceutical industry in general, and GMP-compliance management in 
specific, had been addressed only in few studies and there was a very limited theoretical 
background for the research topic. Sustainability management in supply chains was identified 
to be the closest link to a solid theoretical framework. Research question was refined 
accordingly to include some fundamental issues within the research topic (e.g. confirming 
the significance of the topic in the first place). 
 
Planning data collection: External information on companies’ supply chain management 
practices is very limited, therefore it was apparent from the beginning that the data needed 
for the study would be internal. As mentioned previously, the research topic was rather 
unexplored, and the existing theoretical ground limited. For this reason, it was not practical 
to use any structured data gathering methods, as there was no solid framework to build on. 
This ruled structured interviews and surveys out from the data collection methods. 
Practicalities also prevented performing narrative research, as in the scope of this study 
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gathering narrative data would be extensively time consuming in the context of Master’s 
thesis and getting access would could prove to be impossible. Pharmaceutical companies are 
required to maintain a standard operation procedure system to describe how the company 
operates in different GMP-related activities, including supplier management. The main 
purpose of standard operation procedures is to guide internal personnel, which makes them 
an excellent source of information on how the company operates. However, internal standard 
operation procedures are usually considered confidential, and getting access is again seen 
challenging. In addition, the standard operation procedures may not always fully reflect the 
practice, and the data collected through standard operation procedures is limited.  
Table 4.1 Research design and conduction process (adapted from Eisenhardt, 1989) 
Step Purpose 
Getting started Designate a preliminary research question to specify the 
research area and concentrate efforts to this specific area 
Preliminary literature 
review 
Review work done within the designated research area and 
refining the research question based on review findings 
Planning data collection Identify and design the methods for gathering data 
Selecting sample cases Identify companies relevant to the research 
Entering the field Request and interview persons relevant to the study within 
the identified companies 
Within-case and cross-
case data analysis 
Identify unique and common patterns from and across cases 
Shaping hypotheses Build solid and justifiable hypotheses from data and search 
underlying causes 
Enfolding literature Search similarities and differences to sustainability 
management theory 
Concluding research Present findings and implications 
 
For the above reasons, guided and semi-structured interviews were selected as the main data 
collection method. As Eriksson & Kovalainen (2008) define qualitative interviews, they “are 
research vehicles, the purpose of which is to produce empirical materials for the study in 
question”. According to Eriksson & Kovalainen (2008), guided and semi-structured 
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interviews are useful when studying what and how questions, advantages being a rather 
systematic approach combined with flexibility. Interview outline was adapted from themes 
identified from supply chain sustainability management literature. 
 
Selecting sample cases: Sample of this research consists of six international pharmaceutical 
companies. Criteria for sample companies was quite straight-forward: the companies were 
expected to have an international external supply chain, perform supply chain GMP-
compliance management in-house and be at least medium-sized. No geographical limitations 
were used. Sampling aimed to find typical cases fulfilling the above criteria, in order to get 
a cross-section from the pharmaceutical industry (Patton, 1990).  
 
Interviewees in the sample companies were expected to work in quality department and be 
responsible from supply chain GMP-compliance management in corporate or manufacturing 
site level. In one case, the interviewee was in a region level, being responsible from Europe 
supply. In two interviews, there were more than one participant who were interviewed at the 
same time in a group interview. Table 5.2 summarizes the case companies and interviewees, 
their location, title and level in the company. 
 
Entering the field: Companies were approached by email and in some cases through a follow-
up phone call. Emails were sent to general company emails, but also directly to potential 
persons identified through social media (e.g. LinkedIn). Interviewees were requested to 
reserve one hour for the interview. 
 
Interviews were semi-structured and each lasted about an hour. One interview was conducted 
face-to-face and the others through VoIP software (e.g. Skype). All the interviews were 
recorded and transcribed into text. For interview outline, main themes and two to four main 
questions to each theme were prepared before the interview, however, this outline was not 
strictly followed to maintain flexibility within the research topic.  
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Table 4.2: Case companies and interviewees 
Company Interviewee 
location 
Company 
HQ 
Interviewee 
level 
Interviewee 
title(s) 
Main 
business 
A Finland Finland Corporate Partner 
Management 
Manager, QP 
Proprietary 
products 
B India India Corporate President - 
Corporate 
Quality 
Contract 
manufacturing 
C Spain Sweden Manufacturing 
site 
Quality 
Manager & 
Qualified 
Person 
 
Quality 
Auditor, QP 
Contract 
manufacturing 
D Finland Japan Region Responsible 
person 
Finland 
Proprietary 
products 
E Switzerland Switzerland Corporate Head of 
QA/GMP, 
Director 
Global 
Quality 
Management 
Proprietary 
products 
F Finland Germany Manufacturing 
site 
Responsible 
person 
Finland 
 
Quality 
compliance 
specialist 
 
Quality 
compliance 
specialist 
Proprietary 
products 
 
Within-case and cross-case data analysis:  Case-specific data was analyzed through within-
case and cross-case analysis as suggested by Eisenhardt (1989). The researcher first 
familiarized himself with the individual cases, which started already when transcribing the 
interviews. This phase included open coding of the information collected through interviews 
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and identifying unique features of each case within themes used in the interviews. These 
features were further refined, forming an iterative and incremental analyzing process. The 
case-specific features were tabulated to help the cross-case analysis. In the next phase, 
common patterns and major differences were searched across cases. 
 
As presented by Dubois & Gadde (2002), a case is not the only parameter affecting to theory 
creation, but also defined empirical boundaries, analytical framework and existing theory 
have an effect on this process. In this study, the empirical world was clearly limited to 
pharmaceutical supply chain management from quality department perspective, and the data 
analysis focused on identifying patterns concerning the different actors and activities within 
this empirical boundary. 
 
Data analysis is usually done against an analytical framework that can be of two different 
types: tight and prestructured or loose and emergent (Dubois & Gadde, 2002). This study did 
not start with a predefined framework, but rather it was created and re-created during the data 
analysis and interpretation steps. Loose and emergent analytical framework was necessary 
for this study as the existing theory is built on traditional supply chain management and could 
not be used to build a prestructured framework for the study purposes, as this study 
concentrated on creating new theory under a very specific context to contemplate the existing 
theory. 
 
On a broader level, the data analysis process used in this study and especially in depicting 
the framework presented in the results section is well described by what Dubois & Gadde 
(2002) call matching: going back and forth between transcribed interviews, tabulated case-
specific features, empirical context, existing literature and the framework (results). One 
important method used was to first sketch on paper processes for the individual companies 
and then, through iterative review of interview data and the sketched processes, refine them 
and find similarities and common features between the companies. One important feature of 
the matching process is that data should not be forced to fit a defined model, rather the model 
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should be developed from the data. Finally, Dubois & Gadde (2002) conclude that the 
matching process has no obvious pattern as matching theory and reality can take various 
directions. 
 
Shaping hypotheses: A generic framework on supply chain GMP-compliance management 
practices and insights of the phenomenon was constructed based on the common patterns 
found in data analysis. The main differences across cases were reflected as well. It was kept 
in mind that the number of cases limited the generalization of results and jumping into too 
specific conclusions was avoided. The purpose of the framework is more to outline and 
describe the phenomena rather than to explain it. 
 
Enfolding literature: The framework built above was compared to the frameworks found in 
relevant literature. Similarities were underlined and main differences reflected against the 
empirical data gathered from interviews. 
 
Concluding research: Conclusion included summarizing the main findings from the previous 
steps and discussing about theoretical contribution and implications for supply chain GMP-
compliance and sustainability management as well as supplier and risk management in 
general. 
 
4.4 Research validity, reliability and ethical concerns 
This section will be concluded by a critical evaluation of validity and reliability of this 
research. Also ethical concerns are discussed. Yin (2003) mentions three different types of 
validity that are useful in evaluating research quality: construct validity, internal validity and 
external validity. By construct validity, he means pursuing objective interpretation and 
avoiding subjective conclusions. Internal validity can be understood as deducing solid causal 
relationships between conditions, and external validity as the generalizability of the research 
results (Yin, 2003). Finally, reliability of a study means that the same results would be 
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received if a study would be repeated by another researcher following the same procedures 
(Ibid.). 
 
According to Yin (2003), construct validity can be enhanced by gathering data from different 
sources, or submitting case reports for reviewing. In this study, obvious additional sources 
could have been company standard operating procedures or interviewing additional parties 
such as case companies’ suppliers or additional persons within the company. Unfortunately, 
in the scope of a Master’s Thesis, this would not have been possible even if these sources 
would have been accessible. Even though full case reports were not reviewed by the 
interviewees, they remained available after the interviews for clarifying issues and this 
possibility was used in several occasions. Also, researcher focused on objectivity and fact-
based interpretations for the full duration of the study. 
 
Internal validity was constructed through thorough data analysis. Special attention was given 
to justifiability of conclusions made. The data itself was rather unambiguous and the research 
topic tightly defined, which helped drawing conclusions. If the data was not fully supporting 
conclusions, this is clearly brought up in the results section. 
 
External validity in the context of this study is the hardest to evaluate of the three types of 
validity, as there are no other studies to compare to. Case companies were quite different 
from each other in terms of main business and location, but their management procedures 
and views on the topic were similar, which implies that the results should be generalizable to 
the industry. There were, however, only six companies and this conclusion would need 
support from other studies to be confirmed. Furthermore, the differences between the case 
companies may limit generalizability of the study as well.  As the research topic itself exists 
only within pharmaceutical industry, it is obvious that the specific results are not applicable 
to other industries. Nevertheless, there were many similarities to supply chain sustainability 
management theory, which would imply that the results may be partly applicable to 
sustainability field as well. There is more discussion on this topic in the results section. 
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To ensure reliability of the study, the methodological procedures as well as research design 
and conduction steps have been described accurately and in detail. Data gathering performing 
was performed coherently, recording and transcribing the interviews, and the data was 
analyzed systematically. Possible biases between the interviewer and interviewee were 
decreased by creating an open and trustworthy interview environment. All in all, 
transparency is reinforced whenever possible. 
 
A lot of effort was also put to minimizing ethical concerns. Name of the companies are not 
published and their description kept minimal, keeping in mind the demands of the study. In 
few cases where the case companies could be identified from their description, the 
interviewee was contacted and agreed that the possible compromise of company name is 
alright. At the end of every interview, interviewees were asked whether anything confidential 
aroused from the discussion, and they had the possibility to contact interviewer also after the 
interview. 
 
4.5  Limitations of the study 
There are several limitations that are good to keep in mind. First, the number of case 
companies is quite limited to catch all the features of the studied phenomenon. The study 
results are to be considered more directional than precise. Second, as there was no theoretical 
framework about the studied phenomenon and interviews were semi-structured, it is possible 
that something essential was left outside the interview themes. Interviews were kept as open-
ended as possible, but this possibility remains. Third, the researches has been working in the 
pharmaceutical industry for several years, and might have brought some biased views to the 
study. This possibility was identified from the beginning and objectivity was enforced 
throughout the study. Finally, one has to consider the possibility that interviewees were 
biased, describing more how they would want the situation to be than how it actually is. A 
good example of this is the following question: when evaluating new suppliers, what kind of 
weight are compliance issues given compared to price, HSE and other factors? The 
interviewees as quality assurance representatives were quite consistent in answering that 
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compliance issues are the most important ones, but does this really reflect the reality? 
Unfortunately, in the scope of this study, it was not possible to confirm interview data from 
secondary sources or additional interviews, so the question of interviewee bias remains open.  
 
5. THE PHARMACEUTICAL INDUSTRY 
5.1 Introduction 
Pharmaceutical industry is by far the most regulated industry there is, which can be explained 
by the prevalent risks. Regulations have evolved step-wise, usually as a reaction to severe 
occurrences causing deaths or other health effects among patients. One of these occurrences 
is the thalidomide crisis, where pregnancy related morning sickness was treated with 
thalidomide-based products without appropriately studying the health effects of the drugs as 
regulations were basically nonexistent. Thalidomide products caused severe birth defects for 
approximately 10 000 newborns before the products were withdrawn from the markets. 
Thalidomide case is the basis for today’s stricter regulation and post-marketing 
pharmacovigilance activities. 
 
Besides using understudied drugs, health risks may arise for example from mixing up drugs 
in the user level, mixing up raw materials at the manufacturing phase, contaminating drug 
products with toxic materials or using infected injectables. Furthermore, many active 
substances (the core raw material of medicines) have a very narrow therapeutic window and 
are very potent, meaning that the intended health effect may easily turn into health-
threatening effects if wrong amount of the active substance (AS) is administrated. As 
different active substances are many times handled in the same manufacturing facilities, 
cross-contamination of different active substances is also seen as a serious threat. 
 
There is a big array of different regulations posed to oversee and prevent these threats, 
starting from the very early steps of development (good laboratory practice, GLP; good 
clinical practice, GCP) and reaching to the actual manufacturing stage (good manufacturing 
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practice, GMP), distribution (good distribution practice, GDP) and also to post-market 
actions (good pharmacovigilance practice, GVP). As the topic of this thesis is related to the 
manufacturing activities of products intended to the EU region, the most relevant set of 
regulations for this thesis is good manufacturing practice in the European Union, or the EU 
GMP. Before going further to GMP specifics, the next paragraph explains the regulatory 
requirements for individual pharmaceutical products. 
 
5.2 Marketing authorization 
To sell a pharmaceutical product in the EU region, the product has to be granted a marketing 
authorization (MA) by the relevant authority. There are several application pathways, but for 
the purposes of this thesis, the most relevant topics are contents and maintenance activities. 
MA is assigned to a certain legal entity, usually a pharmaceutical company, called the 
marketing authorization holder. Marketing authorization holder is responsible for 
maintaining the MA and keeping it up-to-date. From the authority side, the MA is maintained 
by the relevant authority, which can be on national or EU-level, depending on the route that 
the MA has been applied. 
 
MA consists of different modules describing different aspects of the product, such as quality, 
safety and efficacy. The exact content may vary between products, but MAs usually specify 
for example detailed composition of the final product, manufacturing plant(s) for active 
substances and the final product and description of manufacturing process and control steps, 
location of chemical and microbiological testing, chemical and physical specifications of the 
final product and description of the analysis methods, description of the packaging material 
quality, dimensions and artwork and so forth. The intention of this listing is to show that, as 
every pharmaceutical batch produced have to comply with the registered MA, changing 
something such as the AS manufacturer, is never quite as simple as in many other industries. 
In case of changes, the marketing authorization holder must update the MA by a variation, 
from which basically all considering other than minor changes must be pre-approved by the 
relevant authority before the applied change can be implemented. To get an approval to the 
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variation, the marketing authorization holder has to show that the product quality is not 
affected, which may mean costly and time-consuming studies. 
 
5.3 Good manufacturing practice 
The foundation and legitimacy of EU GMP is laid out in two European Commission 
directives, 2003/94/EC for medicinal products for human use and 91/412/EEC for veterinary 
use. The principles and guidelines set by these directives are interpreted into more practical 
level by Commission’s Guide to Good Manufacturing Practice that is divided into three 
different parts and 19 related annexes. Even though there are different GMP guidelines 
written by different organizations or consortiums for many different purposes (for example 
manufacture of excipients), official GMP begins from the manufacture of active substances 
and reach to the manufacture of medicinal products and related activities. These related 
activities include maintaining premises and equipment, documentation, personnel training 
and qualification, quality control and quality assurance of products, managing outsourced 
activities, handling product complaints and product recalls and so forth. Other authorities 
outside the EU, such as FDA in United States or Anvisa in Brazil, have their own GMP 
guidelines that are mainly harmonized with the EU GMP, some differences remaining. EU 
regulations place the marketing authorization holder as in the center of requirements: the 
responsibility of compliance and product quality and safety remains with the marketing 
authorization holder, never mind where and by which party different manufacturing practices 
are performed. 
 
GMP guidelines are strongly enforced by the different authorities. Manufacturing 
pharmaceuticals (or active substances) is subject to a manufacturing authorization granted by 
the local authority, usually after a rigorous on-site inspection. To bring pharmaceuticals to 
the EU markets, for example, a manufacturing site also has to have a GMP certificate granted 
by an authority of an EU member country. These inspections are perhaps the most important 
way of enforcing the GMP guidelines and usually last several days with several inspectors. 
The EU GMP certificate, if granted, is valid from one to three years, depending on the amount 
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and criticality of deficiencies found, after which a re-inspection is needed to receive an 
updated GMP certificate. In case the company fails to pass the inspection, a non-compliance 
report is issued to the manufacturing site and importation of products to the EU region is 
usually banned. Both EU GMP certificates and non-compliance reports are published in 
EudraGMDP database public for everyone. In addition to the authority inspections, every 
pharmaceutical batch has to be fully analyzed within the EU region before it can be released 
to the markets, meaning that imported batches have to be re-analyzed within the EU. Also 
other regulations exist, but the purpose of this chapter is not to give a holistic view of the 
prevailing requirements, but rather to give an overview of the regulatory environment 
pharmaceutical companies and their supply chains are working in. 
 
Compared to the sustainability governance where NGOs are one of the most important 
pressure groups, in GMP-compliance governance they hold only a very minor role, limited 
mostly to publishing guidelines. This might be due to the strong role that authorities have 
taken, making it unnecessary for NGOs to play a bigger role. 
 
5.4 Nature of pharmaceutical supply chains 
Considering the nature and risks related to pharmaceutical products, GMP requirements and 
MA procedure, it is obvious that pharmaceutical supply chains tend to be quite rigid. To 
transfer production of a certain product from one supplier to another one, an organization has 
to include evaluation of risks related to the new supplier, conduct process validation, transfer 
analytical methods into a new laboratory, assure product stability remains unchanged and 
update the MA through variations. These tasks are time-consuming (year may not be 
enough), require a great amount of effort and resources and are costly. One would therefore 
think that initial supplier qualification would be considered essential in pharmaceutical 
supply chains. 
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According to the EU GMP requirements, an organization has to audit its AS suppliers as well 
as any supplier taking part in the pharmaceutical product manufacture and ensure that they 
comply with GMP. These audits should usually be conducted with 3 year’s frequency for 
active suppliers. Only for excipients suppliers there’s a possibility to follow a risk-based 
approach. This audit requirement creates an interesting setting for the supply chain 
management: whereas in other industries audit is rather something that’s performed if 
supplier is considered high-risk, in the pharmaceutical industry one has to audit even smallest 
of its suppliers (if they belong to the categories defined above). This is in addition to the fact 
that authorities are usually auditing the same suppliers in parallel. Moreover, one of the 
supplier audit goals may well be to ensure that the supplier can pass an authority audit and 
thus be able to receive and maintain the needed certificates for supplying its products to the 
EU market. 
 
There has been a lot of discussion around the shift of pharmaceutical production to Asia and 
its effects on product safety (for example Drakulich & Van Arnum, 2009; Rosania, 2010; 
Harris, 2009; Harris, 2014), but detailed information about the proportion of pharmaceutical 
products actually manufactured outside EU is scarce. One reliable information source is the 
EudraGMDP database maintained by European Medicines Agency (EMA) and listing for 
example issued EU GMP certificates & non-compliance reports. Based on a report run from 
this database, Figure 4.1 presents the number of AS GMP certificates issued since 01.01.2013  
in the top 20 countries and Figure 4.2 presents the number of issued GMP certificates for 
pharmaceutical production for human use since 01.01.2013 in top 20 countries.  
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Figure 5.2: EU GMP certificates for pharmaceutical production for human use (not including 
packaging, analysis, importation, exportation and batch certification activities) issued since 
01.01.2013 per country, top 20 countries (numbers obtained from a report run from a report 
run from EudraGMDP database on 28.03.2016) 
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Figure 5.1: EU GMP AS certificates issued since 01.01.2013 per country, top 20 countries 
(numbers obtained from a report run from EudraGMDP database on 28.03.2016) 
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From these figures alone, it is quite obvious that India and China are major players in the AS 
side and especially India in the pharmaceutical production side. However, a big majority of 
GMP certificates have still been issued to EU member countries, especially to sites in 
Germany and France. It should be noted that these figures do not take into account the number 
of products or production volumes, as one production site and all its products are usually 
under one GMP certificate, be the site’s production volume in grams or tons. If it is assumed 
that the production in EU is more specialized into novel and smaller-volume products and 
that the production in India and China is directed more to production of bigger ‘bulk’ 
products, the relevance of these two countries grows even bigger. This assumption is backed 
up by statement the European Medicines Agency already in 2005 stating that “approximately 
80% of active substances used in the manufacture of medicinal products within the EEA are 
manufactured outside of the EEA”. It is also commonly acknowledged that United States is 
highly dependent on active substances manufactured in Asia (Harris, 2009). 
 
5.5 Globalization of pharma supply chains and authority enforcement 
The rising importance of Asia and specifically India and China in pharmaceutical production 
has raised product safety and quality concerns, especially after the Heparin crisis of 2008 
(Rosania, 2010). Heparin produced in China from pig intestines and used as AS caused nearly 
150 deaths in the United States, when several heparin batches were (possibly deliberately) 
contaminated with another substance so similar to heparin that the used analytical methods 
were not able to separate the two substances (Rosania, 2010). Later on, it was acknowledged 
that the related heparin manufacturing site had not been inspected by US FDA or the Chinese 
regulators. 
 
After the heparin crisis, the US FDA has increased number of its oversees inspections 
significantly (Rosania, 2010), which has revealed many misconducts of Asian AS and 
pharmaceutical manufacturers, such as data fraud and data integrity issues (for example 
Siddiqui & Chatterjee 2014; Siddiqui, 2015; Edney, 2016). Figure 4.3 presents the number 
of companies per country listed in FDA’s list of manufacturing sites under import alert (sites 
54 
 
that are restricted to export some or any AS pharmaceutical products to the United States). It 
is however not only the FDA that has increased its oversee focus – also European authorities 
have issued many non-compliance reports to foreign manufacturers. Figure 4.4 presents the 
number of issued non-compliance reports issued by EU authorities since July 2009 per 
country. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: number of manufacturing sites currently under U.S. import restrictions 
(http://www.accessdata.fda.gov/cms_ia/importalert_189.html?source=govdelivery&utm_medium=e
mail&utm_source=govdelivery, accessed on 29.03.2016) 
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Figure 5.4: GMP non-compliance reports issued by EU authorities since 07/2010 per 
country (numbers obtained from EudraGMDP database on 28.03.2016) 
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Both China and India clearly stand out from the above figures. Even though there is a number 
of other countries in the list and both India and China are bigger in number of pharmaceutical 
companies than their peers, the differences are drastic. The motives behind the enforcement 
acts of especially US FDA have been questioned and they have been accused of politicizing 
to protect domestic industry from international competition (Harris, 2014). Nevertheless, a 
company choosing a supplier from China or India seems to be taking a bigger risk of supplier 
compliance issues than a company favoring Western suppliers. 
 
It should be noted that placing an import alert to a manufacturing site by US FDA and issuing 
a non-compliance reports by the European authorities are the ultimate steps, and the 
authorities in both continents have other, softer, means to handle observed deficiencies that 
may already limit the supply of products. On the other hand, the number of companies listed 
above represent a small fraction of the listed countries’ pharmaceutical manufacturing sites 
and when comparing to the number of EU GMP certificates presented in Figures 4.1 and 4.2, 
it becomes obvious that a much bigger fraction has passed an authority inspection.  
 
6. GMP-COMPLIANCE MANAGEMENT IN PHARMACEUTICAL SUPPLY 
CHAINS 
The results of this study are presented in the following order: this chapter will begin by 
presenting nature and perceived significance of the studied phenomenon, and then move to 
describing the actual management processes and organizational aspects.  
 
6.1 Pharma supply chains and significance of compliance risks 
When acquiring of the biggest risks in company’s supply chain, the views of different 
companies varied somewhat. Four of the six informants directly mentioned supply shortage 
risks, either with active substances or pharmaceutical products. The possible shortages were 
thought to arise from several different reasons, varying from GMP-compliance issues to 
natural accidents such as fire. Two interviewees brought up risks to products or materials 
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during transportation, such as temperature excursions. Also the risk of “not being aware of 
what’s happening at supplier’s end”, or losing control, was mentioned by two informants. 
Compliance risks were directly brought up in two of the interviews, even though indirectly 
it can be interpreted to concern all the companies (for instance insufficient change control or 
insufficient transportation controls can be perceived as compliance issues). The emphasis on 
different risks is interpreted to rise from companies’ different supply chain profiles: with 
some companies the weight is more on raw materials, whereas with others in actual 
pharmaceutical products. Also the size of external supplier pool and geographical factors 
may have an effect. 
 
When asking of the biggest challenges, one of the informants mentions that “with today’s 
regulations, when one has to be aware of everything even though you are not the 
manufacturer, that is quite a challenge”. Another informant describes the challenges as 
follows: 
The biggest challenges are continuous communication, and transparency between the 
suppliers. What I am trying to say, as we are sitting in a remote place, we cannot 
control every day their operations in terms of compliance. So we need to have a 
process, which ensures the transparency, what is happening at their plant, so we can 
assure our quality of the product 
This theme was clearly a common concern for almost all of the interviewees: establishing 
and maintaining trust, transparency and open communication between the separate suppliers 
and the company. One informant raised the challenge of acquiring appropriate control of 
transportation and another one the challenge of getting company products prioritized with 
suppliers that are supplying for several other customers. 
All of the interviewees considered compliance risk to be of relevance in the pharmaceutical 
industry. As the individual companies had quite different supply chains, the risk perceived in 
the company’s own supply chain varied. It was obvious that the interviewees from companies 
with more complex supply chain considered the risk to be bigger compared to their peers 
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from companies with simpler supply chains. None of the informants considered the risk to 
be big in their internal supply chain, but the risk was considered to lie within the external 
supply network. A general view was that the risk is bigger with Asian companies, compared 
to their peers in Europe or North America, where the risk was perceived to be much smaller. 
Nevertheless, one of the informants described that “the world has changed in a way that 
compliance issues raise more often and losing [manufacturing] license occurs ever more. And 
not only in India, but also in Europe and these cases have become closer” 
 
The consequences of supply chain GMP-violations were considered to vary from rejecting 
individual batches to large-scale product recalls and ultimately effects on patients through 
supply shortages. From the company perspective, most severe consequences were thought to 
be export limitations on some certain markets or withdrawal of a manufacturing license. In 
only two out of the six interviews were reputational damages brought up, but clearly they 
must be existent and are basically two-fold: the reputational costs from patients’ side in case 
of supply shortages, especially with life-saving drugs, and the reputational costs of being 
publicly notified in the authority websites or databases. 
 
All the informants expressed that there has been an increase in the authority compliance 
enforcement, basically through two different routes: through establishing new requirements 
and guidelines that establish new or stricter requirements, especially from the European 
authorities, and increased authority inspection activity, especially form the US FDA. One of 
the interviewees stated that from her view, the product quality has remained the same and 
real risks related to product quality have not increased, but ‘authority risk’ has increased 
through stricter standards and requirements. The interviewees seemed to experience this 
change in two ways: on one side, they have to oversee that their suppliers are adapting to the 
new requirements, and on the other side they have to be more alert regarding authorities 
inspecting their suppliers. Five out of the six interviewees experienced that compliance risk 
has increased during recent years: one had actually experienced a rise in the number of 
compliance-related incidences, one perceived the increased risk through increased authority 
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activity, two through increased requirements and one saw the overall risk to be the biggest 
with new suppliers. One of the six informants experienced that the compliance risk has been 
reduced as the authorities have taken more control, reducing the number of non-compliant 
suppliers. Four of the six interviewees saw efficient supplier management to bring 
competitive advantage, whereas the two remaining saw it more as something that has to be 
managed carefully in order to enable business continuity, but not as a real source of 
competitive advantage. 
 
One observation that ought to be noted is that none of the companies had established their 
own standards for their suppliers, but all based their requirements on GMP-guidelines. 
Companies may imply some company-specific requirements above the GMP-regulations, 
especially in case of non-standard products, but GMP was always the basis of these 
requirements. One of the companies was also producing medical devices and thus following 
the relevant ISO-guideline, but otherwise no other international quality standards than GMP 
was mentioned. Relying solely on GMP is probably due to the fact that this gives the 
companies the most legitimacy over their suppliers: GMP is not a standard that the company 
alone would require, but is based on legislation and compliance by the suppliers is required 
to run their business in the first place. GMP is thus more enforcing than for instance ISO 
standards, as they don’t limit the license to manufacture products if a company fails to 
comply. 
 
One shortly covered topic during the company interviews was the importance of networks. 
None of the interviewees considered their informal networks to be of importance in supply 
chain compliance management and only half of the companies belonged to a formal industry 
consortium where supply chain management is addressed. In these consortiums, the main 
benefit was seen to be saving audit resources through sharing audit reports instead of 
organizing separate audits for each company. Other benefits included benchmarking, sharing 
knowledge and to some extent training. The consortiums, however, were nowhere near 
replacing companies’ own supplier management or even some parts of it, instead they were 
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more of an extension of it. There might be an element of gaining power through networking 
over big global suppliers, but this was not brought up during the interviews. 
 
6.2 Organization of GMP-compliance management 
Among the six companies, there were essentially two different approaches into organizing 
the supplier GMP-compliance management: in four of the six companies, the responsibility 
was in the corporate level, whereas in two of the companies, individual manufacturing plants 
were responsible for managing their own suppliers. If the GMP-compliance management lied 
in the corporate level, the role of individual manufacturing plants was mainly to report the 
possible incidences with suppliers to corporate:  
Manufacturing plants have lesser responsibilities, because what we do is, this central 
team will qualify and approve the supplier… The only sites would do, is, they should 
only agree on suppliers. And any non-conformance comes, from those suppliers, they 
will come back and inform the central supplier group, so that they will see the 
performance of the supplier 
If, on the other hand, the responsibility lied within the individual manufacturing plants, the 
role of corporate level was coordinating, information sharing between different sites and 
setting up and maintaining the supplier GMP-compliance management system to be locally 
adjusted and followed by the individual manufacturing plants. In this case, the corporation 
could also assume responsibilities of GMP-compliance management for suppliers supplying 
materials to several of the individual manufacturing sites. The level of corporate coordination 
varied between the two companies, one being more stand-alone and the other more dependent 
on corporate oversight. The reason for choosing one of the two approaches was not apparent 
from the interviews, but the researcher was left with an understanding that it is strongly 
related to the uniqueness of the individual manufacturing sites, with companies having 
standard manufacturing sites following the corporate model and companies having unique 
manufacturing sites following the stand-alone model. 
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The main responsibility from supplier GMP-compliance management lied within quality 
department in all of the six companies, which is not surprising as this is required by the GMP-
guideline. Some of the companies had established a separate compliance department for 
managing supplier GMP-compliance management system, its activities including sending 
and evaluating questionnaires, performing audits and maintaining the system. In other 
companies, these tasks were not assigned to dedicated persons or departments, but were 
performed by the quality department personnel along with their other responsibilities. Even 
though the responsibility lied within the quality department, all interviewees emphasized the 
importance of cooperation with other department, such as procurement, research and 
development and own production. 
 
6.3 Supplier GMP-compliance management process 
Before going to details of the GMP-compliance management process, it should be 
emphasized that all the companies had a traditional supplier management (and supply chain 
management) process that was managed by the company’s purchasing (or equivalent) 
department. GMP-compliance management was thus not something that would replace or 
make the traditional supplier management obsolete. The GMP-compliance management 
process was discovered to be independent from, but also interrelated to, the traditional 
supplier management process. The traditional supplier management process in the 
companies, even though not in the scope of this thesis, is outlined in this chapter from the 
parts being relevant and connected to the GMP-compliance management process. 
 
Figure 6.1 presents a descriptive framework of the supplier GMP-compliance management 
process and its linkages to traditional supplier management process, depicted based on the 
conducted interviews. The process was similar in all of the six companies and followed on a 
broad level the same phases and principles. To outline the differences and avoid over-
generalization, the differences between companies are outlined in the following chapters and 
steps that were omitted by half or more of the companies are marked to Figure 6.1 with grey 
colour. As presented in the figure, GMP-compliance management is divided into two 
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different phases, new supplier qualification and existing supplier management, each having 
three separate steps.  
 
 
 
 
 
 
 
 
 
 
 
 
6.4 New supplier qualification 
Evaluation of new suppliers begins from the traditional supplier management process, where 
procurement department searched the possible candidates and was in charge in selecting the 
ones to be assessed further based on business requirements. Even though managed by 
department, also other departments including quality, own production and research and 
development, were usually participating in this assessment phase.  In four of the companies 
the candidate assessment included an on-site visit to the supplier and a general-level review 
of the supplier’s quality management system to already eliminate suppliers clearly not 
fulfilling the basic GMP-requirements. In two of the six companies, the candidate assessment 
was based purely on business requirements and didn’t include an assessment of supplier’s 
quality management system. In its simplest form, the process is as described by one of the 
informants: 
 
Figure 6.1: supplier GMP-compliance management process and its linkages to  
traditional supplier management process 
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Purchasing unit chooses the supplier and proposes it to quality. According to our 
procedures, we have to collect some information from the supplier in order to decide 
if the supplier [can] be certified… This is indicated in procedure and purchasing 
department [will] ask for this information 
After the supplier assessment in the traditional supplier management process, the remaining 
candidate(s) were passed on to the GMP-compliance management process. As described in 
earlier chapters, the main responsibility of this process lied always within the quality 
department, but the interviewees also emphasized the importance of cooperation with other 
departments. The companies had some differences in their new supplier process, but all of 
them had three clear steps: pre-evaluation, GMP-audit and qualification. 
 
 Pre-qualification 
The purpose of pre-qualification in all companies was to make sure that the remaining 
supplier candidate(s) pass a minimum GMP-compliance threshold, gather more information 
on them and evaluate whether the candidate can be passed forward to the audit phase. As 
audits require a lot of resources, not all the supplier candidates could be audited and it was 
deemed highly important to be able to eliminate suppliers clearly not complying to GMP-
requirements already at the pre-evaluation phase. Pre-evaluation step included in all of the 
companies gathering pre-defined information on company’s quality management system, 
mostly in form of a supplier self-evaluation questionnaire. It also utilized information 
gathered on the candidate assessment phase. Two of the six companies used questionnaire as 
the only pre-evaluation tool, whereas others could also organize a visit to the supplier’s 
premises to gather more information and review the physical manufacturing facilities. This 
visit could take place already in the supplier assessment phase. There were some differences 
between active substance and final product supplier evaluation: with active substances, pre-
evaluation also included analyzing the material according to defined specifications and, 
depending on the nature of the final product, performing trial manufacturing with the 
supplier’s active substance. Only one of the six informants mentioned analyzing final 
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products to be included in the pre-evaluation step. Pre-evaluation was followed by supplier 
candidate GMP-audit. 
 
 GMP-audit 
The purpose of this research was not to describe the audit process itself, but to concentrate 
on the nature, purpose and limitations of this supplier qualification step. As mentioned 
earlier, supplier GMP-audits are required by the EU-GMP and thus performed by default, 
before the supplier can be taken into use. The purpose of this step is quite obvious: to verify 
that supplier is complying to the current GMP-requirements, including that there are no issues 
risking the end user’s health. That said, some of the limitations of auditing in general are also 
commonly acknowledged: audits capture only a specific moment in time, and what takes 
place after the audit can’t fully be reflected by the audit. Secondly, there is always a time 
limitation, and not all relevant topics can be covered during an audit. This fact produces a 
sampling-kind of a nature of audits: auditor(s) will always have to choose what to include to, 
and what to exclude from the audit, taking samples of the company’s performance. 
 
All the interviewees placed a very high importance to the GMP-audit, and it was clearly the 
main tool in evaluating supplier candidate’s compliance level. One challenge in audits that 
all informants raised was time constraint: as audits demand a lot of resources also from 
supplier candidate’s end, the number of audit dates accepted by the supplier can be quite 
limited. When enquiring about the audit days assigned to a given supplier, one of the 
informants described this challenge as follows: 
[We assign] one day. It is hard to get more time because companies receive a lot of 
audits… if you buy a lot of product then it is possible. In some cases, you have to pay 
a fee for the audit 
As the above citation reveals, especially in Western countries, getting more than one audit 
day may be impossible, especially with active substance manufacturers. With finish product 
supplier’s, getting more than two audit dates was told to be challenging to almost all of the 
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companies. Again, the challenge was bigger in Western countries than for example in Asia. 
Available time can be extended by adding more auditors, but this will also increase needed 
resources and costs, and will only be beneficial to a certain point. 
 
There was a clear, partly formal and partly informal, risk assessment made when allocating 
resources to audits or, in other words, deciding how many days the audit should last and the 
members to be included in the audit team. Formal as some basic principles were described 
by written procedures, and informal as the specifics were decided case-by-case. Written 
principles might for example require allocating more audit resources to suppliers located in 
third countries than in Western countries, suffering from bad authority inspection history, or 
manufacturing sterile products compared to non-sterile products. Case-by case 
considerations could include the exact number of days and auditors, as well as experience 
and expertise areas of the auditors. Audit teams consisted of a lead auditor, meaning a person 
having more experience on auditing and leading the audit team, and subject matter experts, 
meaning a person having specific experience and knowledge on one specific subject, such as 
microbiological laboratory practices. 
 
 Qualification decision 
The audit step was followed by a supplier qualification decision or, in other words, a decision 
of whether the supplier achieves required GMP-compliance level and can be accepted to the 
company’s supplier pool.  Three of the six companies made this decision directly based on 
the audit result, meaning that if the audit was acceptable, the supplier could be qualified. One 
of the informants described this process as follows: 
The outcome of the audit is a last step. For the selection, it is the project leader from 
the manufacturing that will decide with a quality manager in charge of this project 
and they will decide if they will want to work with the supplier or not. If the audit is 
positive, then it is ok to work with them. If the audit is negative, as a head of quality, 
I will have to jump in and ensure changes at the supplier, or we take some other 
measures to improve the GMP-compliance of the supplier 
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Three of the six companies conducted some additional means before qualifying the supplier, 
one of them conducting stability testing on the materials. Only two remaining companies 
conducted a formal GMP-compliance risk assessment after the audit before qualifying the 
supplier, one of them making this assessment only to suppliers located outside Europe. The 
purpose of this risk assessment was to fully evaluate the supplier compliance risks and the 
actions needed to manage them, and it followed the normal risk assessment principles: 
gathering all the relevant information from previous steps, evaluating risk factors and 
assigning risk points to them, and evaluating which risks are acceptable and which demand 
further risk mitigation actions. 
 
6.5  Existing supplier management 
When supplier had been qualified through the above process, it entered company’s supplier 
pool and could be used for further projects as well. There was no initial supplier or similar 
status to indicate that there might not yet be much experience with the supplier, nor did any 
of the companies have a process where they would test the supplier with smaller projects 
before granting bigger ones. It was emphasized many times during the interviews, that the 
suppliers could not be seen as generic, but were usually picked for a certain project based on 
their specific capabilities. Once qualified, they could also be used for other projects. Again, 
quality department had the responsibility and mandate for managing GMP-compliance of 
existing suppliers, whereas other supplier management activities were overseen by 
procurement (or an equivalent department). There were three main tools that were the 
backbone of existing supplier GMP-compliance management: quality agreement, risk 
assessment and follow-up audits. All these three means are also required by the EU-GMP. 
 
 Quality agreement 
Before starting the operations, a separate quality agreement has to be signed with the supplier 
to agree on the GMP-related activities and responsibilities. This agreement was described by 
one of the companies as the foundation of the supplier GMP-compliance management, a tool 
to set the principles and nature of the supplier relationship.  
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 Risk assessment 
For existing qualified suppliers, all companies performed a risk assessment. Its purpose in 
five of the six companies was not to fully list the risks prevalent to a certain supplier, but 
rather to build an outline on the supplier risk profile. One of the informants describes the risk 
assessment as follows: 
…risk assessment is done on a regular basis to define how often we have to repeat 
the audit. So after the supplier is selected, we start to work with them and after one 
year we have some KPIs [key performance indicators] and we evaluate, make a risk 
assessment, on these KPIs and depending on the outcome of the risk assessment, we 
define if we make an audit after one year or two and so on 
This step didn't thus follow the three risk assessment phases presented in Figure 2.1, but 
comprised of giving risk points to a certain supplier in pre-defined risk factors and assessing 
the risk level of a certain supplier through the sum these points. Examples of the evaluated 
risk factors includes criticality of the product dosage form (topical, oral, intramuscular, 
intravenous etc.), scale of different dosage forms manufactured, geographical location, 
business effect, authority inspection history, GMP-compliance history and certain GMP-
compliance key performance indicators, such as number of customer complaints proportional 
to sales. This risk level was then used in defining frequency for the supplier follow-up GMP 
audits. The risk assessment was updated on a yearly basis to evaluate the follow-up GMP 
audit frequency.  Only one of the companies performed a supplier specific risk assessment, 
that followed the traditional risk assessment phases. This risk assessment was initially 
conducted already in the supplier qualification decision phase and updated yearly for the 
existing suppliers.  
 
 Follow-up audits 
The main purposes of follow-up audits were to oversee and enforce issues agreed in the 
quality agreement, evaluate the manufacturing process against existing product marketing 
authorization, verify that the supplier has implemented corrective actions for concerns raised 
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in previous audits, and that the supplier’s GMP-compliance level has overall remained above 
the required threshold. Same challenges and limitations exist as in the initial audit. The 
minimum frequency for follow-up audits required by EU-GMP is 3 years, but with the risk 
assessment it could be raised to one or even half year. Audit result was first approved in the 
quality, and if major issues were discovered, they could be elevated within the quality 
department or to cross-functional teams. 
 
 Other supplier and risk management tools 
As described in earlier chapters, EMA and FDA are keeping public databases of their 
inspection history and issuing reports of supplier non-compliance (EMA) and critical GMP-
violations (FDA). Several companies were actively following these databases to be alerted 
of possible supplier problems with authorities. Finding one’s supplier to be rejected by either 
of EU or U.S. authorities would naturally be a signal that company’s own GMP-compliance 
management process has failed and following these databases by its nature a rather 
retroactive tool for GMP-compliance management.  
 
This incidence of finding authorities lifting an import ban or placing other restrictions to a 
company’s supplier, as well as discovering supplier critical GMP-compliance by any other 
ways, would call for urgent actions to secure company’s supply, or at least minimize the 
caused shortages. A bit surprisingly, only two of the six companies had a clear process to 
follow in case of supplier critical GMP-violations were recognized, either from internal or 
external sources. This process included calling up a cross-functional director meeting, 
evaluating the case and needed actions, contacting the supplier in regards of corrective 
actions and supplier termination in case the problems could not be solved. 
 
As acknowledged in the literature review part of this thesis, back-up suppliers are a common 
way of controlling the risk of supply chain disruptions. This was also true for the companies 
in case of active substance suppliers: all companies except one had back-up suppliers at least 
for the most critical active substances. With drug product suppliers, however, the picture is 
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quite different. As described by one of the informants, having back-up suppliers would mean 
“one should transfer manufacturing to another manufacturer, go through changes in 
manufacturing authorization, [manufacturing] process should be validated, so the transfer 
becomes too expensive…”. In general, the interviewees described the costs and resources 
needed for qualifying and maintaining a back-up supplier to be so significant that it has been 
considered impossible to maintain one, even when taking into consideration the risks related 
to keeping only one source of products. These costs include for instance transferring 
manufacturing capability, conducting separate process validations and updating product MAs 
for two different sites. Only one company of the six had back-up suppliers for drug products, 
and only for the most critical products. It should be pointed out that none of the companies 
measured costs related to supplier GMP-compliance violations that caused supply chain 
disruptions or other negative impacts on the company’s economic performance.  
 
6.6 Links to traditional supplier management 
All the companies had quarterly or half-yearly cross-departmental internal meetings to 
review individual supplier performance, including also GMP-compliance issues. These 
meetings were organized to have a holistic view on the supplier performance and were the 
main link between traditional supplier management and GMP-compliance management 
processes. To measure this performance, companies used different key performance 
indicators, such as number of customer complaints proportional to sales, number of rejected 
batches and number of manufacturing-related deviations. Some of these key performance 
indicators were the same as in the yearly risk assessment. These internal meetings were 
usually followed by meeting with the supplier to discuss topics raised in the internal 
meetings. Only one of the six companies had launched a GMP-compliance related supplier 
development program, meaning in this case sending their own employees to the supplier’s 
premises to train and develop supplier GMP-performance.  
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It is quite obvious, that there is also other, informal interaction between the traditional and 
GMP-compliance management processes, and that these two don’t work in isolation of each 
other outside the formal linkages. One type of these informal interactions discovered was 
elevating topics from the GMP-compliance management process to the traditional supplier 
management process to get a better or quicker response from the supplier. It is also given that 
the purchasing department usually having the overall supplier responsibility cannot manage 
the supplier relationship without being also aware of the supplier’s GMP-compliance status 
and possible risks and problems. When examining Figure 6.1, it should thus be kept in mind 
that it is an illustration depicted based on the companies’ formal processes and 
responsibilities.  
 
One final note to be made is that the traditional supplier management process varied in the 
companies depending on the relative importance of the supplier to the company, minor 
suppliers having a reduced process compared to more important ones. The GMP-compliance 
management process, however, remained the same for all suppliers, be they minor or 
important. This feature can be traced to the EU GMP requirements, which do not make any 
separations between important and minor suppliers. 
 
7. CONCLUSIONS AND DISCUSSION 
This chapter will assess research findings through the research questions, and reflect these 
findings to the reviewed literature on SCM, supplier selection, evaluation and qualification 
process, SSCM and SCRM. For the sake of clarity, it is beneficial to start this assessment 
from the lower-level context of GMP-compliance management in pharmaceutical industry 
and then draw connections to the higher-level contexts of supply chain, sustainability and 
risk management. 
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7.1 Significance and nature of GMP-compliance risk 
The first of the three research question to be addressed is: what is the significance and nature 
of GMP-compliance risk? This thesis started by claiming that GMP-compliance must be of 
relevance to pharmaceutical companies – it is one of the very basic conjectures of the 
companies’ and their supply chain’s business. Without compliance, the companies are simply 
not allowed to sell drug products. As presented in chapter five, the GMP-regulations are 
strongly monitored and enforced by different authorities, making GMP-compliance risk a 
continuous threat to company’s existence if it is not managed appropriately. 
 
This claim was supported by the interviews: all companies had established a process for 
managing their supply chain GMP-compliance, and expressed that not complying to the 
regulations is not an option. GMP-compliance was also brought up as one of the biggest risks 
in their supply chain by several interviewees. The significance of GMP-compliance risk is 
thus clearly established. 
 
The nature of GMP-compliance risk can be approached from two angles - through perceived 
consequences and through perceived challenges. Immediate consequences are similar to 
those of any quality-related risks: if the drug products are not safe to consume or lacking the 
effect they should, companies may need to withdraw products from markets, causing 
financial losses and usually short-term shortages.  On the other hand, if a supplier loses its 
ability to supply due to import restrictions or refusal of licenses, the consequences are similar 
to those of supply chain disruptions (product stock-outs), but may also lead to product recalls. 
Besides the immediate consequences, product shortages, market actions and especially 
product-related adverse reactions or patient deaths may also cause severe reputational 
damages to companies, extending the financial losses from concerning individual products 
to the overall business. The GMP-compliance risk can thus clearly be classified as belonging 
to supply risks, but it can also be considered to bear similarities to man-made macro risks 
and being more significant than supply risks: even though not comparable to war or political 
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tremor, a non-compliance report from the European authorities or a warning letter from FDA 
may well destroy supplier’s business if it is banned from selling its products. 
 
From challenges point of view, supply chain GMP-compliance bears similarities to the 
challenges of governing supply chain sustainability that were presented in Table 3.2, with 
some differences. Informational & knowledge and communication challenges are the most 
apparent commonalities that were also highlighted by the interviewees: retrieving reliable, 
comprehensive and credible information from suppliers was described to be challenging in 
terms of GMP-compliance, as well as establishing effective communication routes. Even 
though compliance and power challenges were not directly mentioned by the interviewees, 
it is nonetheless obvious that these are applicable to GMP-compliance management. Here, 
finding complimentary ways to govern compliance besides audit programs and finding 
common ways to interpret and implement GMP-guidelines can be considered the main points 
for overcoming these challenges. Legitimacy challenges are also apparent to exist in GMP-
compliance management. Finally, geographical challenges may be the only one of the gaps 
presented by Boström et al. (2015) that is not directly applicable to GMP-compliance 
management: where in terms of sustainability, effects of violations can be ignored by buyers 
due to the geographical distances, the violations in GMP-compliance usually affect the 
product end consumers and are thus much closer and may cause a much bigger negative 
effect to the business of the buyer organization. Overall, from the challenges point of view, 
GMP-compliance risk can be considered to be similar to sustainability risk in its nature. 
 
7.2 Supplier and risk management in a highly regulated and enforced environment 
Let us next turn our attention to the second research question: how is supplier and risk 
management constructed in a highly regulated and enforced environment? As presented in 
chapter 4, the EU GMP already withholds and requires a certain framework for supplier 
GMP-compliance management: API and drug product manufacturers have to be audited with 
a minimum of three-year cycle, companies have to perform a yearly risk profile assessment 
for individual suppliers and it has to be the quality department, who manages the overall 
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process. None of the interviewees had questioned these basic principles or tried to modify 
them, rather these principles had been used as the focal point to the management processes. 
With some companies, it seemed that the supplier GMP-compliance management process 
was a direct copy of the requirements, without any or very little further development. Even 
with the companies having more elements than the minimum in their process, the basic 
elements were clearly observable: audit, qualification decision, quality agreement, yearly 
supplier risk profile assessment and follow-up audits. 
 
Even though present with every company, pre-evaluation and qualification steps differed the 
most between companies. With some, GMP-compliance aspects were already thoroughly 
considered during overall candidate assessment and in the initial site visits, whereas with 
some companies the pre-evaluation was done solely by quality assurance with a 
questionnaire. Same division existed in the supplier qualification phase, some of the 
companies considering a supplier to be qualified after it had passed an audit, whereas others 
concluded a holistic GMP-compliance risk assessment including risk mitigation actions, for 
which supplier audit was only one of the aspects. This study did not go as far to details as 
mapping the contents of quality agreements, specific points included in the formal risk 
assessments or supplier audit agendas, but differences must exist between companies, some 
of the companies doing the different steps more thoroughly and rigorously than others. 
 
EU-GMP does not require any certain type of organization for GMP-compliance 
management process within the quality department, which leaves the companies open hands 
for allocating responsibilities to different levels and departments inside the quality function. 
Organization is perhaps where the companies differed the most from each other, on two 
aspects: having supplier GMP-compliance on a corporate level versus manufacturing site 
level, and having a separate “GMP-compliance” team managing centrally the overall process 
versus dividing the responsibility of different process steps to different quality functions and 
having thus a decentralized process. 
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One interesting aspect of the supplier GMP-compliance management is its connection to the 
traditional supplier management process. It was deductible from the interviews that these two 
processes have in past been almost totally isolated from each other, connecting only at the 
beginning (supplier candidate is fed to the GMP-compliance management process) and end 
(supplier is qualified and allowed to the company’s supplier pool or rejected and deterred 
from supplying to the company). As seen in Figure 6.1, many of the companies have 
implemented integrative elements between the two processes: GMP-compliance evaluation 
is already started at the “traditional” candidate assessment stage, concerns related to GMP-
compliance are shared in cross-functional meetings and cooperation between the quality and 
purchasing departments overall is encouraged. 
 
When moving away from the research context, it is clear that many of the ground assumptions 
do not exist outside the pharmaceutical industry, and the framework presented in Figure 6.1 
is not directly applicable to other industries. Especially two of these assumptions should be 
highlighted: mandate given for the quality department, admitting independent authority in 
decision making and basing these decisions solely on quality aspects (and excluding for 
instance economic aspects), and the rigorous authority enforcement through inspections, 
controlling that the individual process steps are in line with established requirements (rather 
than evaluating effectiveness of the overall process).  
 
This acknowledgement leads to the main conclusion in regards to the outlying research 
question: in an environment of strong regulation and enforcement, supplier and risk 
management is constructed starting with the established regulations and building these 
processes on them, rather taking generally acknowledged or “best practice” processes as a 
starting point and adjusting them to the regulations. That said, the study results showed that 
even though the processes were established on grounds of regulations, there was a tendency 
of developing them towards these general practices and integration. The next chapter will 
continue from this conclusion. 
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7.3 The effects of strong regulation and authority enforcement 
In this last chapter, I will address the third research question:  what are the impacts that 
strong regulation and authority enforcement impose to supplier and risk management 
practices? As presented by Johnson & Flynn (2015; Table 2.1), traditional supplier selection 
begins with organization’s strategic requirements and then continues into assessing supplier 
risks versus expected returns, possible purchasing strategies and evaluating supplier 
performance in regards of quality, price, sustainability and other factors. As with the 
traditional supply chain management, also sustainable supply chain management places 
organization’s strategic values to the very core of supplier selection and management process. 
As presented in the Figure 6.1, candidate assessment lied in the traditional supplier 
management process and even though most of the companies included GMP-compliance 
partially to the assessment phase, it was evident that the main focus on supplier GMP-
compliance level was only after the supplier candidate(s) had already been chosen. Since 
supplier candidates are assessed without a full GMP-compliance evaluation, and rather fed 
to the GMP-compliance management process after the assessment to verify that the minimum 
GMP-level is achieved, there is a clear gap between the company’s strategy and supplier 
GMP-compliance management. Proposing that EU-GMP regulations have alone caused this 
gap would probably be over-exaggerating, but as will be presented below, it is obvious that 
they have influenced the way companies have built their processes. 
 
The study of Luzzini et al. (2014; Table 2.2) showed, that supplier evaluation is normally 
conducted through three distinctive steps – collecting first preliminary general information 
about the supplier, then gathering more in-depth information on supplier capabilities to 
produce the actual product and allowing the supplier to organization’s supplier pool, and 
assessing the supplier performance through different key performance indicators. The main 
insight from the traditional supplier management for the purpose of this thesis is that supplier 
requirements arise from organization’s strategy and there are no separate processes for 
managing areas such as quality or sustainability, but these are integrated to the overall 
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process. This doesn’t mean that traditional SCM wouldn’t consider these areas important, 
but it has clearly been beneficial to integrate them to the overall process. 
 
As concluded in the previous chapter, the approach companies had taken in regards of GMP-
compliance management was not as simple: companies had built their GMP-compliance 
management process on the grounds of regulations and requirements, separate from the co-
existent traditional supplier management process. One of the ground reasons for this 
approach is traceable to the GMP-regulations, that place the responsibility of supply chain 
GMP-compliance to quality department and grant them a mandate of independent decision 
making. As quality department has its focus mainly on product quality (and patient safety) 
instead of the overall supplier relationship, this setting can easily create departmental silos 
and even conflicts within an organization. This may especially occur between quality 
department responsible from GMP-compliance and purchasing department responsible from 
the overall supplier relationship. This leads to the first conclusion concerning the impacts of 
regulations: strong regulation, especially if granting independent authority to one department 
over the others, contributes to creating departmental and process-specific silos within an 
organization and reduces integration. 
 
Another implication for building processes according to regulations is that the regulations 
don’t consider variance between companies that is sure to exist, and thus the processes may 
not be optimal for a given company’s business model. This can lead to inefficiencies and 
even contradictions between what is required and what would be the best solution. 
Furthermore, strong regulations coupled with strong enforcement through authority 
inspections can shift the focus from supplier management to complying to regulations. GMP-
audits serve as a good illustration on this: whereas supplier on-site audits are normally 
considered a quite extreme tool and conducted only for the riskiest suppliers, the companies 
performed them by default for every supplier as required by the EU-GMP. As audits are to 
be performed in any case, most of the companies omitted supplier risk assessment, perhaps 
the most important phase in traditional and sustainable supplier selection, evaluation and 
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qualification process, and qualified the supplier solely based on audit. Taking into 
consideration limitations of supplier audits, this leaves companies without a holistic view of 
the supplier and the related risks. The third conclusion is as follows: strong regulation and 
authority enforcement on the other hand reduces flexibility and shifts the focus from 
effectiveness of supplier management process to the compliance of the process itself, and on 
the other, may lead to omitting critical process steps if the consecutive steps are already 
defined by the regulations. 
 
The literature review section on managing supply chain sustainability introduced a link 
between SSCM and dynamic capabilities and some specific dynamic capability categories, 
such as knowledge assessment, supply chain partner development and co-evolving. 
According to the reviewed literature, dynamic capabilities are an extension of more 
traditional SSCM capabilities, a next step, and for a company to be able to develop dynamic 
capabilities, it must have the traditional SSCM practices in place. Both traditional SSCM and 
dynamic capability categories build on supply chain partnership and integration. This study 
did not specifically address dynamic capabilities, but the results strongly imply that the base 
for building dynamic capabilities related to supply chain GMP-compliance management 
process is missing: supplier relationships remain more transactional than collaborative in 
their nature. Actions towards supply chain integration would most certainly create similar 
benefits in the research context as with traditional SCM and SSCM, but they are seemingly 
hard to take as the GMP-compliance management process is not even internally an integral 
part of the overall supplier management process. 
 
In the literature review section, Table 2.3 listed some commonly used risk management 
strategies for overcoming macro risks. Most of these strategies focused on stock and logistics 
management or commercial or marketing aspects and are thus not directly applicable to 
managing GMP-compliance risk. Two strategies are relevant in this manner: flexible supply 
base and make-and-buy. Both of these strategies rely on having an alternative source for 
products, in case the main supplier is for some reason unable to supply its products. This 
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strategy was followed by most of the companies in case of active substances, but due to EU 
GMP-regulations on manufacturing and supplier management, maintaining a back-up supply 
for drug products was deemed so expensive and resource-demanding that only few of the 
companies had pursued this strategy, and only for the most critical drug products. Based on 
the above, I present the following conclusion: regulations can drive costs and resources 
needed for maintaining back-up supply and possibly other risk management strategies so 
high that companies might omit these strategies. 
 
Both strategies managing supply risks presented in literature (see Table 2.4) and the 
framework presented for SSCM by Beske & Seuring (2014; see Figure 3.2) build on strategic 
rather than transactional supplier relationship, supplier development and integration, 
reducing supply chain complexity and choosing carefully the kind of right suppliers and 
monitoring them through pre-defined key performance indicators. Supplier relationship in 
terms of GMP-compliance management in the companies, on the other hand, did not have 
many integrative or strategic elements: supplier development activities were virtually 
missing, early supplier involvement and long-term relationship were not brought up in the 
interviews and learning from and enhancing innovation through suppliers were absent. It is 
true that these elements may exist in the traditional supplier management process, but 
nevertheless they were scarce in GMP-compliance management.  
 
One interesting area bearing similarities between the traditional supplier risk management, 
SSCM and supply chain GMP-compliance management is controlling suppliers through pre-
defined standards:  establishing quality management program, standards and supplier 
certification are common themes for all the three practices. In the research context, standards 
were established by authorities instead of NGOs or companies themselves. Similarly, in the 
research context, certification can be seen to be conducted by the authorities through GMP-
inspections after which, if passed, suppliers were granted a GMP-certificate that are disclosed 
publicly. Likewise, if the inspection was not passed, authorities issued a public non-
compliance certificate. This certification program is a natural way for a company to evaluate 
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the GMP-compliance risk of its supplier: if there is a recent GMP-certificate, the risk is 
considerably lower than if the supplier has not been inspected by authorities. Suppliers not 
passing an inspection can be banned from supplying products before appropriate corrective 
actions and a re-inspection. Even though the EU-GMP requires companies to audit their AS 
and drug product suppliers, as presented in the results section, companies enhance authority 
inspections in their supplier evaluation and risk assessment processes. Thus the following 
conclusion about the effects of authority enforcement is drawn: strong authority enforcement 
and certification schemes transfers responsibility of supplier management and related risks 
partially towards the authorities. 
 
8. MANAGERIAL IMPLICATIONS AND SUGGESTIONS FOR FURTHER 
RESEARCH 
The findings presented above have implications on both private and public sector. Perhaps 
the most valuable insight from this study is that setting industry-specific regulations and 
system for enforcing them may not be as straight-forward as many think. This can have some 
major impacts on how companies operate and create significant inefficiencies as well as 
unintentional shifts of responsibility from companies to authorities. However, as many 
regrettable incidences such as the thalidomide crisis demonstrate, strict regulations are 
necessary to protect health of the masses. It is thus of upmost importance to understand the 
implications of high authority regulation and enforcement. This study was conducted in the 
pharmaceutical industry, which can without doubt be described as one of the strictest industry 
in terms of regulatory demands and control and thus gives an accentuated view of these 
implications. I will first discuss the effects for companies and on an industry-level and then 
proceed to implications for authorities and the society. 
 
As was concluded in the previous chapter, supply chain GMP-compliance management 
processes were designed to comply with the prevalent regulations and there was in several 
cases no or only little tendency to develop these processes beyond compliance to these 
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regulations. It is obvious that from company or business perspective, this causes unnecessary 
inefficiencies and rigidity. Following the recent developments in supplier, risk and 
sustainability management, a better integration of supply chain GMP-compliance 
management to the overall supplier management process would create clear benefits for a 
given company in terms of efficiency and transparency, reduce unnecessary silos within a 
company and encourages cooperation between departments.  Designing the GMP-
compliance management processes as an integral part of holistic supplier management 
process, not only a mere necessity arising from regulations, would most definitely support 
supplier risk management, eliminating weak suppliers at earlier phases, elevating and 
reacting to problems more efficiently et cetera. Furthermore, this would encourage 
companies to refine the meaning and purpose of each process step and introduce 
complementary steps, rather than conducting the steps defined in regulations without 
considering their relevance. 
 
This is not to say that companies should ignore the regulations or try to shift the responsibility 
assigned in this case to the quality department and risk facing sanctions or other regulatory 
actions, rather they should build the processes first as a fit to company strategy and business 
model and secondary as a fit to regulations. Regulations will most probably require adjusting 
the established processes, but it is the principle of linking the process to company’s strategy 
from the beginning that matters. 
 
From authority and societal perspective, two of the conclusions presented in the previous 
chapter are of considerable significance: partial shift of responsibility towards authorities and 
arising costs of risk management strategies. The shift of responsibility applies especially in 
connection with high regulatory enforcement and oversight, where the authorities themselves 
use the power to interpret whether a specific supplier is approvable or not and also use this 
power in practice. Companies will enhance the available information on authority inspection 
history in their supplier evaluation and risk assessment processes, which leads to favoring 
suppliers with strong inspection history over the ones with no or limited history and the 
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companies that have failed an authority inspection. I will not go on arguing whether this 
phenomenon itself is good or bad (or both), but it is nevertheless something that should be 
acknowledged. 
 
Raising the costs of maintaining back-up supply of a certain product in specific and other 
risk management strategies in general, on the other hand, may have more immediate and far 
reaching consequences. Having no or limited contingency planning for keeping a certain drug 
product on markets makes the supply chain seemingly vulnerable for macro risks, both man-
made and natural, and thus long-lasting disruptions. In case of pharmaceuticals, this may 
evidently mean shortages of life-saving or maintaining drugs and patient deaths. Even though 
the consequences would not be as devastating, they may still have a negative effect to society 
and individual patients. This is something that the regulators must take into account and 
concerns especially health-related industries where the regulations are by default stricter than 
in other industries. 
 
This study was one of the first ones to address the impacts of high authority regulation and 
enforcement, thus it contains many assumptions and the conclusions made remain to be 
challenged. As mentioned in the method chapter, the purpose of this study was not to capture 
a holistic view but rather give a directional overview on the studied phenomenon. To validate 
the conclusions made, it would be beneficial to examine other highly regulated industries to 
see if they bear similarities. The actual effects of the implications raised in this chapter should 
also be addressed in more detail. Finally, given the scope and limitations of this study, there 
might be a need to refine some of the presented results and frameworks to better represent 
the general approaches and decisions made by different companies after gathering more data 
and, due to a rather limited number of samples, some relevant insights could have been 
omitted. This calls for further research. 
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